Try our mobile app

Switch to company model in classical logic    *

General information

Country: UNITED STATES

Sector: Drug Manufacturers — General

Categories: @vaccine-makers   

Merck & Co., Inc. is a global health care company that delivers health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products, which it markets directly and through its joint ventures. The Company has operations in pharmaceutical, animal health, and consumer care.
Website: merck.com



Growth: Pretty weak revenue growth rate 8.9%, there is slowdown compared to average historical growth rates 9.1%. The revenue growth dynamics is unstable Site traffic for the last 3 months showed a change of +3.7%

Profitability: LTM EBITDA margin is negative, -6.1%. On average the margin is improving unsteadily. Gross margin is high, +77.6%. In the last quarter the company beat the estimated EPS, +6.1%. The company was ahead of estimated EPS in 100% of quarters (showing a gain of +$0.16 per share on average)

Cash Flow Generation: Dividend yield for the last twelve months 3.5%. Free cash flow yield -2.5% (LTM)

Undervaluation: Fundamental value created in LTM (estimate)


Entry Point: Share price is 19.6% higher than minimum and 31.4% lower than maximum for the last 3 years

AI Insight: the companies with similar growth trajectories, EBITDA margin, industries and geography on average are valued 1.7x by EV / Sales multiple , the company can be 60.4% overvalued

Insiders: For the last 3 months insiders bought company shares on $0.1 mln (0.000% of cap.)

Key Financials (Download financials)

Ticker: MRK
Share price, USD:  (+2.0%)91.27
year average price 113.99  


year start price 128.84 2024-02-26

max close price 132.96 2024-06-24

min close price 83.01 2025-02-14

current price 91.16 2025-02-24
Common stocks: 2 528 810 012

Dividend Yield:  3.5%
Last revenue growth (y/y):  +8.9%
Last growth of EBITDA (y/y):  +40.1%
Historical revenue growth:  +9.1%
Historical growth of EBITDA:  +4.5%
EV / Sales: 4.2x
Margin (EBITDA LTM / Revenue): -6.1%
Fundamental value created in LTM:
Market Cap ($m): 230 526
Net Debt ($m): 26 140
EV (Enterprise Value): 256 666
Price to Book: 5.1x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / Sales

Potential dynamics

News


2025-02-24accessnewswire.com

Investors in Merck & Co., Inc. Should Contact Levi & Korsinsky Before April 14, 2025 to Discuss Your Rights - MRK

2025-02-24accessnewswire.com

ROSEN, NATIONAL TRIAL LAWYERS, Encourages Merck & Co., Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – MRK

2025-02-24accessnewswire.com

Merck & Co., Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before April 14, 2025 to Discuss Your Rights - MRK

2025-02-24globenewswire.com

Shareholders of Merck & Co., Inc. Should Contact Levi & Korsinsky Before April 14, 2025 to Discuss Your Rights – MRK

2025-02-24accessnewswire.com

Class Action Filed Against Merck & Co., Inc. (MRK) Seeking Recovery for Investors - Contact Levi & Korsinsky

2025-02-24accessnewswire.com

Merck & Co., Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before April 14, 2025 to Discuss Your Rights - MRK

2025-02-24prnewswire.com

MRK Purchasers Have Opportunity to Lead Merck & Co., Inc. Securities Fraud Lawsuit

2025-02-23accessnewswire.com

Investors in Merck & Co., Inc. Should Contact Levi & Korsinsky Before April 14, 2025 to Discuss Your Rights - MRK

2025-02-23globenewswire.com

ROSEN, HIGHLY RECOGNIZED INVESTOR COUNSEL, Encourages Merck & Co., Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – MRK

2025-02-23accessnewswire.com

Merck & Co., Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - MRK
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol MRK MRK MRK MRK MRK MRK MRK MRK MRK
reportedCurrency USD USD USD USD USD USD USD USD USD
cik 310 158 310 158 310 158 310 158 310 158 310 158 310 158 310 158 310 158
fillingDate 2024-11-06 2024-08-05 2024-05-03 2024-04-11 2023-11-03 2023-08-07 2023-05-05 2023-02-24 2022-11-03
acceptedDate 2024-11-06 16:05:36 2024-08-05 16:02:11 2024-05-03 16:10:43 2024-04-11 16:05:38 2023-11-03 16:10:43 2023-08-07 16:09:00 2023-05-05 07:39:41 2023-02-24 16:22:30 2022-11-03 16:28:44
calendarYear 2024 2024 2024 2023 2023 2023 2023 2022 2022
period Q3 Q2 Q1 Q4 Q3 Q2 Q1 Q4 Q3
revenue 16 657M 16 156M 15 775M 14 630M 15 962M 15 035M 14 487M 13 830M 14 959M
costOfRevenue 4 080M 4 293M 3 540M 3 912M 4 264M 4 024M 3 926M 3 881M 3 934M
grossProfit 12 577M 11 863M 12 235M 10 718M 11 698M 11 011M 10 561M 9 949M 11 025M
grossProfitRatio 0.755 0.734 0.776 0.733 0.733 0.732 0.729 0.719 0.737
researchAndDevelopmentExpenses 5 862M 2 886M 3 992M 9 627M 3 307M 13 321M 4 276M 3 775M 4 399M
generalAndAdministrativeExpenses 0 0 0 504M 0 0 0 0 0
sellingAndMarketingExpenses 0 0 0 2 300M 0 0 0 0 0
sellingGeneralAndAdministrativeExpenses 2 731M 2 708M 2 483M 2 804M 2 519M 2 702M 2 479M 2 687M 2 520M
otherExpenses 0 203M 203M 224M 236M -172M -89M 75M 0
operatingExpenses 8 495M 5 594M 6 475M 12 431M 5 826M 16 023M 6 755M 6 462M 6 919M
costAndExpenses 12 673M 9 887M 10 015M 16 343M 10 090M 20 047M 10 681M 10 343M 10 853M
interestIncome 127M 69M 73M 70M 73M 109M 112M 95M 40M
interestExpense 330M 310M 303M 310M 317M 277M 227M 235M 244M
depreciationAndAmortization 1 186M 1 064M 984M 964M 1 014M 903M 991M 892M 959M
ebitda 5 606M 7 380M 7 020M -455M 5 998M -4 861M 3 873M 3 536M 4 781M
ebitdaratio 0.337 0.454 0.445 -0.031 0.376 -0.323 0.267 0.256 0.32
operatingIncome 3 984M 6 269M 6 036M -1 419M 5 998M -4 861M 2 882M 2 644M 3 822M
operatingIncomeRatio 0.239 0.388 0.383 -0.097 0.376 -0.323 0.199 0.191 0.255
totalOtherIncomeExpensesNet 106M -263M -366M -627M -252M -323M 768M 869M -239M
incomeBeforeTax 4 090M 6 006M 5 670M -2 046M 5 620M -5 335M 3 650M 3 513M 3 583M
incomeBeforeTaxRatio 0.246 0.372 0.359 -0.14 0.352 -0.355 0.252 0.254 0.24
incomeTaxExpense 929M 545M 903M -821M 870M 637M 825M 495M 330M
netIncome 3 157M 5 455M 4 762M -1 226M 4 745M -5 975M 2 821M 3 017M 3 248M
netIncomeRatio 0.19 0.338 0.302 -0.084 0.297 -0.397 0.195 0.218 0.217
eps 1.25 2.15 1.88 -0.48 1.87 -2.35 1.11 1.19 1.28
epsdiluted 1.24 2.14 1.87 -0.48 1.86 -2.35 1.11 1.18 1.28
weightedAverageShsOut 2 532M 2 534M 2 533M 2 554M 2 537M 2 539M 2 538M 2 536M 2 533M
weightedAverageShsOutDil 2 541M 2 544M 2 544M 2 554M 2 546M 2 539M 2 551M 2 548M 2 542M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link

Balance Sheet Statement

Property 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol MRK MRK MRK MRK MRK MRK MRK MRK MRK
reportedCurrency USD USD USD USD USD USD USD USD USD
cik 310 158 310 158 310 158 310 158 310 158 310 158 310 158 310 158 310 158
fillingDate 2024-11-06 2024-08-05 2024-05-03 2024-04-11 2023-11-03 2023-08-07 2023-05-05 2023-02-24 2022-11-03
acceptedDate 2024-11-06 16:05:36 2024-08-05 16:02:11 2024-05-03 16:10:43 2024-04-11 16:05:38 2023-11-03 16:10:43 2023-08-07 16:09:00 2023-05-05 07:39:41 2023-02-24 16:22:30 2022-11-03 16:28:44
calendarYear 2024 2024 2024 2023 2023 2023 2023 2022 2022
period Q3 Q2 Q1 Q4 Q3 Q2 Q1 Q4 Q3
cashAndCashEquivalents 14 593M 11 346M 5 671M 6 909M 8 644M 5 660M 9 707M 12 694M 11 145M
shortTermInvestments 0 50M 40M 252M 168M 718M 680M 498M 103M
cashAndShortTermInvestments 14 593M 11 396M 5 711M 7 161M 8 812M 6 378M 10 387M 13 192M 11 248M
netReceivables 11 381M 11 642M 12 572M 11 072M 11 674M 11 030M 10 415M 9 450M 9 482M
inventory 6 244M 6 469M 6 510M 6 358M 6 131M 5 930M 5 863M 5 911M 5 614M
otherCurrentAssets 8 143M 8 740M 6 652M 7 577M 5 337M 6 639M 6 737M 7 169M 7 217M
totalCurrentAssets 40 361M 38 205M 31 445M 32 168M 31 954M 29 977M 33 402M 35 722M 33 561M
propertyPlantEquipmentNet 23 446M 23 221M 23 045M 24 488M 22 526M 22 231M 21 758M 21 422M 20 424M
goodwill 21 697M 21 161M 21 181M 21 197M 21 183M 21 195M 21 209M 21 204M 21 160M
intangibleAssets 17 010M 16 984M 17 572M 18 011M 19 199M 19 665M 19 857M 20 269M 21 368M
goodwillAndIntangibleAssets 38 707M 38 145M 38 753M 39 208M 40 382M 40 860M 41 066M 41 473M 42 528M
longTermInvestments 575M 1 649M 1 588M 1 584M 2 687M 1 214M 1 290M 1 015M 984M
taxAssets 0 876M 922M 0 1 018M 996M 1 442M 1 795M 0
otherNonCurrentAssets 864M 10 534M 10 096M 9 227M 8 160M 9 191M 8 838M 7 733M 9 584M
totalNonCurrentAssets 63 592M 74 425M 74 404M 74 507M 74 773M 74 492M 74 394M 73 438M 73 520M
otherAssets 13 579M 0 0 0 0 0 0 0 0
totalAssets 117 532M 112 630M 105 849M 106 675M 106 727M 104 469M 107 796M 109 160M 107 081M
accountPayables 3 586M 3 519M 3 514M 3 922M 3 509M 3 442M 3 680M 4 264M 3 371M
shortTermDebt 3 149M 3 071M 3 077M 1 657M 887M 2 839M 2 672M 1 946M 1 936M
taxPayables 4 330M 2 777M 2 398M 2 649M 1 981M 1 489M 1 872M 1 986M 1 698M
deferredRevenue 0 2 777M 2 398M 4 634M 3 858M 1 489M 0 0 2 417M
otherCurrentLiabilities 18 521M 16 693M 16 110M 15 481M 14 840M 15 624M 16 779M 18 029M 15 274M
totalCurrentLiabilities 29 586M 26 060M 25 099M 25 694M 23 094M 23 394M 23 131M 24 239M 22 998M
longTermDebt 34 982M 34 717M 31 142M 33 683M 33 972M 34 072M 28 074M 28 745M 28 482M
deferredRevenueNonCurrent 0 0 0 928M 0 0 0 0 0
deferredTaxLiabilitiesNonCurrent 0 876M 922M 871M 1 018M 996M 1 442M 1 795M 2 417M
otherNonCurrentLiabilities 0 7 329M 8 262M 7 864M 7 343M 7 265M 8 244M 8 323M 31 835M
totalNonCurrentLiabilities 34 982M 42 922M 40 326M 43 346M 42 333M 42 333M 37 760M 38 863M 39 559M
otherLiabilities 8 404M 0 0 0 0 0 0 0 0
capitalLeaseObligations 0 0 0 928M 0 0 0 0 0
totalLiabilities 72 972M 68 982M 65 425M 69 040M 65 427M 65 727M 60 891M 63 102M 62 557M
preferredStock 0 0 0 0 0 0 0 0 0
commonStock 1 788M 1 788M 1 788M 1 788M 1 788M 1 788M 1 788M 1 788M 1 788M
retainedEarnings 61 384M 60 187M 56 697M 53 895M 57 082M 54 198M 62 039M 61 081M 59 928M
accumulatedOtherComprehensiveIncomeLoss -5 371M -5 361M -5 274M -5 161M -4 916M -4 900M -4 883M -4 768M -4 743M
othertotalStockholdersEquity -13 299M -13 032M -12 847M -12 941M -12 708M -12 393M -12 110M -12 110M -12 515M
totalStockholdersEquity 44 502M 43 582M 40 364M 37 581M 41 246M 38 693M 46 834M 45 991M 44 458M
totalEquity 44 560M 43 648M 40 424M 37 635M 41 300M 38 742M 46 834M 45 991M 44 458M
totalLiabilitiesAndStockholdersEquity 117 532M 112 630M 105 849M 106 675M 106 727M 104 469M 107 796M 109 160M 107 081M
minorityInterest 58M 66M 60M 54M 54M 49M 71M 67M 0
totalLiabilitiesAndTotalEquity 117 532M 112 630M 105 849M 106 675M 106 727M 104 469M 107 796M 109 160M 107 081M
totalInvestments 575M 1 699M 1 628M 1 836M 2 855M 1 932M 1 970M 1 513M 1 087M
totalDebt 38 131M 37 788M 34 219M 36 268M 34 859M 36 911M 30 746M 30 691M 30 418M
netDebt 23 538M 26 442M 28 548M 29 359M 26 215M 31 251M 21 039M 17 997M 19 273M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link

Cash Flow Statement

Property 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol MRK MRK MRK MRK MRK MRK MRK MRK MRK
reportedCurrency USD USD USD USD USD USD USD USD USD
cik 310 158 310 158 310 158 310 158 310 158 310 158 310 158 310 158 310 158
fillingDate 2024-11-06 2024-08-05 2024-05-03 2024-04-11 2023-11-03 2023-08-07 2023-05-05 2023-02-24 2022-11-03
acceptedDate 2024-11-06 16:05:36 2024-08-05 16:02:11 2024-05-03 16:10:43 2024-04-11 16:05:38 2023-11-03 16:10:43 2023-08-07 16:09:00 2023-05-05 07:39:41 2023-02-24 16:22:30 2022-11-03 16:28:44
calendarYear 2024 2024 2024 2023 2023 2023 2023 2022 2022
period Q3 Q2 Q1 Q4 Q3 Q2 Q1 Q4 Q3
netIncome 3 161M 5 455M 4 762M -1 226M 4 745M -5 972M 2 825M 3 018M 3 252M
depreciationAndAmortization 1 186M 1 064M 984M 964M 1 014M 903M 991M 892M 959M
deferredIncomeTax -401M -181M -51M -931M -336M -355M -277M -307M -661M
stockBasedCompensation 195M 203M 176M 167M 164M 169M 145M 145M 139M
changeInWorkingCapital 2 582M -1 012M -3 382M 144M 2 177M -1 636M -2 890M -347M 263M
accountsReceivables 0 0 0 -1 148M 0 0 0 0 0
inventory 0 0 0 -816M 0 0 0 0 0
accountsPayables 0 0 0 0 0 0 0 0 0
otherWorkingCapital 2 582M -1 012M -3 382M 144M 2 177M 0 0 0 0
otherNonCashItems 2 568M 2 439M 2 745M 1 128M -47M 10 595M 545M 1 029M 1 650M
netCashProvidedByOperatingActivities 9 291M 5 637M 3 090M 246M 7 717M 3 704M 1 339M 4 430M 5 602M
investmentsInPropertyPlantAndEquipment -783M -791M -861M -989M -902M -965M -1 007M -1 149M -1 126M
acquisitionsNet -598M 0 -746M 0 902M -10 705M -1 327M 0 -121M
purchasesOfInvestments -169M -49M -15M -251M -117M -25M -562M -494M -5M
salesMaturitiesOfInvestments 50M 60M 260M 169M 704M 285M 500M 12M 335M
otherInvestingActivites -2 345M -289M -14M 1 124M -921M -33M 37M -117M -45M
netCashUsedForInvestingActivites -3 845M -1 069M -1 376M 53M -334M -11 443M -2 359M -1 748M -962M
debtRepayment -1 000 000 3 600M -751M -3M -1 945M -1 750M -1 000 000 -1 000 000 -1 000M
commonStockIssued 0 0 87M 6M 7M 7 965M 30M 0 0
commonStockRepurchased -444M -251M -122M -393M -466M -338M -149M 0 0
dividendsPaid -1 953M -1 986M -1 950M -1 852M -1 855M -1 885M -1 853M -1 750M -1 747M
otherFinancingActivites -27M -147M -78M -3M -10M -234M -81M 197M 45M
netCashUsedProvidedByFinancingActivities -2 425M 1 216M -2 814M -2 245M -4 269M 3 758M -2 054M -1 554M -2 702M
effectOfForexChangesOnCash 294M -82M -138M 186M -157M -93M 87M 366M -412M
netChangeInCash 3 342M 5 675M -1 238M -1 735M 2 940M -4 074M -2 987M 1 494M 1 526M
cashAtEndOfPeriod 14 688M 11 346M 5 671M 6 909M 8 644M 5 712M 9 786M 12 773M 11 279M
cashAtBeginningOfPeriod 11 346M 5 671M 6 909M 8 644M 5 704M 9 786M 12 773M 11 279M 9 753M
operatingCashFlow 9 291M 5 637M 3 090M 246M 7 717M 3 704M 1 339M 4 430M 5 602M
capitalExpenditure -783M -791M -861M -989M -902M -965M -1 007M -1 149M -1 126M
freeCashFlow 8 508M 4 846M 2 229M -743M 6 815M 2 739M 332M 3 281M 4 476M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link

Earning call transcript

2024 q3
2024-10-31 ET (fiscal 2024 q3)
2024 q2
2024-07-30 ET (fiscal 2024 q2)
2024 q1
2024-04-25 ET (fiscal 2024 q1)
2023 q4
2024-02-01 ET (fiscal 2023 q4)
2023 q3
2023-10-26 ET (fiscal 2023 q3)
2023 q2
2023-08-01 ET (fiscal 2023 q2)
2023 q1
2023-04-27 ET (fiscal 2023 q1)
2022 q4
2023-02-02 ET (fiscal 2022 q4)
2022 q3
2022-10-27 ET (fiscal 2022 q3)
2022 q2
2022-07-28 ET (fiscal 2022 q2)
2022 q1
2022-04-28 ET (fiscal 2022 q1)

Press-releases

Show financial reports only

2024-10-28 10:45 ET
Merck and Moderna Initiate Phase 3 Trial Evaluating Adjuvant V940 (mRNA-4157) in Combination with KEYTRUDA® (pembrolizumab) After Neoadjuvant KEYTRUDA and Chemotherapy in Patients With Certain Types of Non-Small Cell Lung Cancer (NSCLC)
2024-10-24 10:45 ET
Merck’s KEYTRUDA® (pembrolizumab) Receives 30th Approval From European Commission With Two New Indications in Gynecologic Cancers
2024-10-16 10:45 ET
Merck’s CAPVAXIVE™ (Pneumococcal 21-valent Conjugate Vaccine) Demonstrates Positive Immune Responses in Adults with Increased Risk for Pneumococcal Disease
2024-10-09 10:45 ET
New Data to be Presented at IDWeek 2024 Reinforce Merck’s Broad and Diverse Vaccines and Infectious Disease Pipeline and Portfolio
2024-10-08 10:45 ET
Merck’s KEYTRUDA® (pembrolizumab) Met Primary Endpoint of Event-Free Survival (EFS) as Perioperative Treatment Regimen in Patients With Resected, Locally Advanced Head and Neck Squamous Cell Carcinoma
2024-10-01 10:45 ET
Merck Completes Acquisition of Investigational B-Cell Depletion Therapy, CN201, from Curon Biopharmaceutical
2024-10-01 10:30 ET
Merck to Hold Third-Quarter 2024 Sales and Earnings Conference Call Oct. 31
2024-09-26 10:45 ET
Merck to Present New Long-Term Data for Tulisokibart (MK-7240), an Investigational Anti-TL1A Monoclonal Antibody, in Inflammatory Bowel Disease at UEG Week 2024
2024-09-25 10:45 ET
Merck Provides Update on Phase 3 KEYFORM-007 Trial Evaluating Investigational Fixed-Dose Combination of Favezelimab and Pembrolizumab for Patients With Previously Treated PD-L1 Positive Microsatellite Stable Metastatic Colorectal Cancer
2024-09-25 10:30 ET
Merck’s KEYTRUDA® (pembrolizumab) Receives New Approvals in Japan for Certain Patients With Non-Small Cell Lung Carcinoma (NSCLC) and Radically Unresectable Urothelial Carcinoma
2024-09-24 12:06 ET
Merck Animal Health Announces Expansion of NOBIVAC® NXT Platform with the First and Only RNA-Particle Technology Vaccine for Feline Leukemia Virus
2024-09-20 11:30 ET
Merck Receives Positive EU CHMP Opinions for KEYTRUDA® (pembrolizumab) Regimens as Treatment for Patients With Two Types of Gynecologic Cancers
2024-09-18 10:45 ET
FDA Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Pemetrexed and Platinum Chemotherapy as First-Line Treatment for Adult Patients With Unresectable Advanced or Metastatic Malignant Pleural Mesothelioma (MPM)
2024-09-17 10:00 ET
Patritumab Deruxtecan Demonstrated Statistically Significant Improvement in Progression-Free Survival Versus Doublet Chemotherapy in Patients with Locally Advanced or Metastatic EGFR-Mutated Non-Small Cell Lung Cancer in HERTHENA-Lung02 Phase 3 Trial
2024-09-16 11:15 ET
PESG Releases Report on Nuvectis Pharma: With Summit Therapeutics Threatening to Dethrone Merck's Keytruda, Nuvectis' NXP900 is One to Watch
2024-09-15 14:30 ET
KEYTRUDA® (pembrolizumab) Plus Chemotherapy Before Surgery and Continued as Single Agent After Surgery Reduced Risk of Death by More Than One-Third (34%) Versus Neoadjuvant Chemotherapy in High-Risk Early-Stage Triple-Negative Breast Cancer (TNBC)
2024-09-15 12:45 ET
Ten-Year Data for Merck’s KEYTRUDA® (pembrolizumab) Demonstrates Sustained Overall Survival Benefit Versus Ipilimumab in Advanced Melanoma
2024-09-14 14:35 ET
KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) in Combination With Transarterial Chemoembolization Significantly Improved Progression-Free Survival Compared to TACE Alone in Patients With Unresectable, Non-Metastatic Hepatocellular Carcinoma
2024-09-14 14:30 ET
Merck’s KEYTRUDA® (pembrolizumab) Plus Chemoradiotherapy (CRT) Reduced Risk of Death by 33% Versus CRT Alone in Patients With Newly Diagnosed High-Risk Locally Advanced Cervical Cancer
2024-09-14 07:15 ET
KEYTRUDA® (pembrolizumab) Plus Trastuzumab and Chemotherapy Significantly Improved Overall Survival (OS) Versus Trastuzumab and Chemotherapy Alone in First-Line Treatment of Patients With HER2-Positive Advanced Gastric or GEJ Adenocarcinoma
2024-09-11 10:45 ET
Merck to Participate in the Bank of America 2024 Global Healthcare Conference
2024-09-11 10:30 ET
Merck Announces Positive Top-line Results from Phase 3 Trial Evaluating Efficacy and Safety of GARDASIL®9 in Japanese Males
2024-09-07 15:30 ET
Ifinatamab Deruxtecan Continues to Demonstrate Promising Objective Response Rates in Patients with Extensive-Stage Small Cell Lung Cancer in IDeate-Lung01 Phase 2 Trial
2024-09-04 10:45 ET
Merck to Present Survival Data and New Research on 10 Investigational or Approved Medicines at ESMO Congress 2024
2024-09-04 10:40 ET
Merck and EyeBio Announce Initiation of Phase 2b/3 Clinical Trial for Restoret™ for the Treatment of Diabetic Macular Edema
2024-09-03 10:45 ET
European Commission Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) as First-Line Treatment of Unresectable or Metastatic Urothelial Carcinoma in Adults
2024-08-29 10:45 ET
Merck to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
2024-08-29 10:30 ET
Merck Provides Update on Phase 3 KEYNOTE-867 and KEYNOTE-630 Trials
2024-08-27 10:45 ET
Merck Announces Phase 3 Trial Initiation for Bomedemstat, an Investigational Candidate for the Treatment of Certain Patients With Essential Thrombocythemia
2024-08-26 10:45 ET
Merck Receives European Commission Approval for WINREVAIR™ (sotatercept) in Combination With Other Pulmonary Arterial Hypertension (PAH) Therapies, for the Treatment of PAH in Adult Patients With Functional Class II-III
2024-08-09 10:45 ET
Merck to Acquire Investigational B-Cell Depletion Therapy, CN201, from Curon Biopharmaceutical
2024-08-08 10:45 ET
Merck Provides Update on Phase 3 KeyVibe-008 Trial Evaluating an Investigational Fixed-Dose Combination of Vibostolimab and Pembrolizumab in Patients With Extensive-Stage Small Cell Lung Cancer
2024-08-06 10:45 ET
Daiichi Sankyo and Merck Enter into Global Development and Commercialization Agreement for MK-6070
2024-08-01 12:00 ET
IDeate-Lung02 Phase 3 Trial of Ifinatamab Deruxtecan Initiated in Patients with Relapsed Small Cell Lung Cancer
2024-07-30 10:30 ET
Merck Announces Second-Quarter 2024 Financial Results
2024-07-26 10:50 ET
Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) as First-Line Treatment for Patients With Unresectable or Metastatic Urothelial Carcinoma
2024-07-23 16:52 ET
Merck Announces Fourth-Quarter 2024 Dividend
2024-07-23 10:45 ET
Merck Announces Topline Results from Phase 2b/3 Trial of Clesrovimab (MK-1654), an Investigational Respiratory Syncytial Virus Preventative Monoclonal Antibody for Infants
2024-07-16 10:45 ET
Merck to Share New Research and Host Community-Focused Symposia at AIDS 2024
2024-07-12 10:45 ET
Merck Completes Acquisition of EyeBio
2024-07-09 12:30 ET
Merck Animal Health Completes Acquisition of Elanco’s Aqua Business
2024-07-09 12:28 ET
Elanco Completes Sale of Aqua Business
2024-07-01 12:15 ET
Merck and Orion Announce Mutual Exercise of Option Providing Merck Global Exclusive Rights to Opevesostat, an Investigational CYP11A1 Inhibitor, for the Treatment of Metastatic Castration-Resistant Prostate Cancer
2024-07-01 10:45 ET
Merck to Hold Second-Quarter 2024 Sales and Earnings Conference Call July 30
2024-06-28 10:53 ET
Merck Receives Positive EU CHMP Opinion for WINREVAIR™ (sotatercept) in Pulmonary Arterial Hypertension (PAH)
2024-06-28 00:18 ET
CDC’S ACIP Unanimously Recommends Merck’s CAPVAXIVE™ (Pneumococcal 21-valent Conjugate Vaccine) for Pneumococcal Vaccination in Appropriate Adults
2024-06-26 23:45 ET
Patritumab Deruxtecan BLA Submission Receives Complete Response Letter from FDA Due to Inspection Findings at Third-Party Manufacturer
2024-06-25 20:05 ET
USDA Approves Merck Animal Health’s NOBIVAC® NXT Canine Flu H3N2 – The First and Only RNA-Particle Technology Vaccine for Canine Influenza
2024-06-17 21:29 ET
U.S. FDA Approves CAPVAXIVE™ (Pneumococcal 21-valent Conjugate Vaccine) for Prevention of Invasive Pneumococcal Disease and Pneumococcal Pneumonia in Adults
2024-06-17 21:15 ET
FDA Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Carboplatin and Paclitaxel as Treatment for Adult Patients With Primary Advanced or Recurrent Endometrial Carcinoma
2024-06-05 10:45 ET
Merck to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
2024-06-03 12:00 ET
Moderna & Merck Announce 3-Year Data For mRNA-4157 (V940) in Combination With KEYTRUDA(R) (pembrolizumab) Demonstrated Sustained Improvement in Recurrence-Free Survival & Distant Metastasis-Free Survival Versus KEYTRUDA in Patients With High-Risk Stag...
2024-05-29 11:15 ET
FDA Grants Priority Review to Merck’s Application for KEYTRUDA® (pembrolizumab) Plus Chemotherapy as First-Line Treatment of Patients With Unresectable Advanced or Metastatic Malignant Pleural Mesothelioma
2024-05-29 10:45 ET
Merck to Acquire EyeBio
2024-05-28 19:12 ET
Merck Announces Third-Quarter 2024 Dividend
2024-05-28 10:45 ET
Merck Announces Phase 3 KEYNOTE-522 Trial Met its Overall Survival (OS) Endpoint in Patients With High-Risk Early-Stage Triple Negative Breast Cancer (TNBC)
2024-05-15 10:45 ET
Merck to Present New Data at 2024 ASCO Annual Meeting Demonstrating Advancements in Novel Oncology Treatment Approaches Across Broad Portfolio and Diverse Pipeline
2024-05-13 10:45 ET
Merck Provides Update on Phase 3 KeyVibe-010 Trial Evaluating an Investigational Coformulation of Vibostolimab and Pembrolizumab as Adjuvant Treatment for Patients With Resected High-Risk Melanoma
2024-05-09 10:45 ET
Merck Provides Update on Phase 3 KEYNOTE-B21 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus Chemotherapy, With or Without Radiotherapy, for Patients With Newly Diagnosed, High-Risk Endometrial Cancer After Surgery With Curative Intent
2024-05-08 10:45 ET
Merck to Participate in the Bank of America Securities 2024 Healthcare Conference
2024-05-01 11:15 ET
Merck Announces Phase 3 KEYNOTE-811 Trial Met Dual Primary Endpoint of Overall Survival (OS) as First-Line Treatment in Patients With HER2-Positive Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
2024-04-29 13:00 ET
Merck Announces Positive Data for V116, an Investigational, 21-Valent Pneumococcal Conjugate Vaccine Specifically Designed for Adults
2024-04-25 10:30 ET
Merck Announces First-Quarter 2024 Financial Results
2024-04-04 10:45 ET
Merck Initiates Phase 3 Clinical Trial of MK-1084, an Investigational Oral KRAS G12C Inhibitor, in Combination with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Certain Patients With Metastatic Non-Small Cell Lung Cancer
2024-04-03 12:00 ET
REJOICE-Ovarian01 Phase 2/3 Trial of Raludotatug Deruxtecan Initiated in Patients with Platinum-Resistant Ovarian Cancer
2024-04-01 10:45 ET
Merck to Hold First-Quarter 2024 Sales and Earnings Conference Call April 25
2024-03-28 10:45 ET
European Commission Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy as Neoadjuvant Treatment, Then Continued as Monotherapy as Adjuvant Treatment, for Resectable Non-Small Cell Lung Cancer (NSCLC) at High Risk of Recurrence in Adults
2024-03-26 22:21 ET
FDA Approves Merck’s WINREVAIR™ (sotatercept-csrk), a First-in-Class Treatment for Adults with Pulmonary Arterial Hypertension (PAH, WHO* Group 1)
2024-03-21 10:45 ET
Merck Provides Update on Phase 3 KEYLYNK-006 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus Maintenance LYNPARZA® (olaparib) for Certain Patients With Metastatic Nonsquamous Non-Small Cell Lung Cancer
2024-03-19 13:00 ET
Merck Announces Positive Data on V116, an Investigational, 21-Valent Pneumococcal Conjugate Vaccine Specifically Designed for Adults, Demonstrated Immune Responses in Adults
2024-03-15 20:23 ET
FarmSee Ltd Announces the Completion of a Minority Investment in its Swine Monitoring Platform
2024-03-15 10:45 ET
Merck’s KEYTRUDA® (pembrolizumab) Plus Chemoradiotherapy (CRT) Significantly Improved Overall Survival (OS) Versus CRT Alone in Patients With Newly Diagnosed High-Risk Locally Advanced Cervical Cancer
2024-03-13 07:00 ET
Merck Announces Plans to Conduct Clinical Trials of a Novel Investigational Multi-Valent Human Papillomavirus (HPV) Vaccine and Single-Dose Regimen for GARDASIL®9
2024-03-11 12:15 ET
Merck Completes Acquisition of Harpoon Therapeutics, Inc.
2024-03-05 11:45 ET
Merck to Participate in the Barclays 26th Annual Global Healthcare Conference
2024-03-04 11:45 ET
Merck to Participate in the Leerink Partners Global Biopharma Conference 2024
2024-02-27 11:45 ET
Merck to Participate in the TD Cowen 44th Annual Health Care Conference
2024-02-23 11:20 ET
Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) in Combination With Chemotherapy as Neoadjuvant Treatment, Then Continued as Monotherapy as Adjuvant Treatment, for the Treatment of Resectable NSCLC at High Risk of Recurrence
2024-02-20 11:45 ET
FDA Grants Priority Review to Merck's Application for KEYTRUDA® (pembrolizumab) Plus Chemotherapy as Treatment for Primary Advanced or Recurrent Endometrial Carcinoma
2024-02-01 11:30 ET
Merck Announces Fourth-Quarter and Full-Year 2023 Financial Results
2024-01-27 15:00 ET
Merck’s KEYTRUDA® (pembrolizumab) Reduced the Risk of Death by 38% Versus Placebo as Adjuvant Therapy for Patients With Renal Cell Carcinoma (RCC) at an Increased Risk of Recurrence Following Nephrectomy
2024-01-26 15:00 ET
Merck’s KEYTRUDA® (pembrolizumab) Significantly Improved Disease-Free Survival (DFS) as Adjuvant Therapy Versus Observation in High-Risk Patients With Localized Muscle-Invasive and Locally Advanced Urothelial Carcinoma After Surgery
2024-01-23 19:44 ET
Merck Announces Second-Quarter 2024 Dividend
2024-01-19 11:45 ET
Merck to Hold Fourth-Quarter and Full-Year 2023 Sales and Earnings Conference Call Feb. 1
2024-01-15 13:15 ET
Merck Animal Health's Fourth Veterinary Wellbeing Study Indicates Progress in Addressing Mental Health Challenges Among Veterinary Teams
2024-01-12 22:30 ET
FDA Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Chemoradiotherapy as Treatment for Patients With FIGO 2014 Stage III-IVA Cervical Cancer
2024-01-08 12:30 ET
Merck to Acquire Harpoon Therapeutics, Further Diversifying Oncology Pipeline
2024-01-05 11:45 ET
Merck Announces Phase 3 Trial Initiations for Four Investigational Candidates From its Promising Hematology and Oncology Pipeline
2024-01-03 11:45 ET
Merck to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
2023-12-22 13:00 ET
Patritumab Deruxtecan Granted Priority Review in the U.S. for Certain Patients with Previously Treated Locally Advanced or Metastatic EGFR-Mutated Non-Small Cell Lung Cancer
2023-12-20 21:30 ET
Merck Provides U.S. Regulatory Update on Gefapixant
2023-12-20 11:45 ET
Merck to Participate in the Goldman Sachs Healthcare C-Suite Unscripted Conference
2023-12-19 11:45 ET
FDA Grants Priority Review to Merck’s New Biologics License Application for V116, an Investigational, 21-valent Pneumococcal Conjugate Vaccine Specifically Designed to Protect Adults
2023-12-18 11:45 ET
European Commission Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy for New First-Line Indications in Advanced HER2-Negative Gastric or GEJ Adenocarcinoma in Tumors Expressing PD-L1 (CPS ≥1) and Advanced Biliary Tract Cancer
2023-12-15 22:00 ET
FDA Approves Expanded Indication for KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) for the First-Line Treatment of Adult Patients With Locally Advanced or Metastatic Urothelial Cancer
2023-12-15 00:00 ET
FDA Approves Merck’s WELIREG® (belzutifan) for the Treatment of Patients With Advanced Renal Cell Carcinoma (RCC) Following a PD-1 or PD-L1 Inhibitor and a VEGF-TKI
2023-12-11 11:45 ET
Merck Animal Health Receives Positive CVMP Opinion for an Injectable Formulation of BRAVECTO® (Fluralaner) for Use in Dogs
2023-12-08 11:45 ET
Merck and Eisai Provide Update on Phase 3 LEAP-001 Trial Evaluating (pembrolizumab) Plus LENVIMA® (lenvatinib) as First-Line Treatment for Patients with Advanced or Recurrent Endometrial Carcinoma
2023-12-07 11:45 ET
Merck Announces KEYLYNK-008 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus LYNPARZA® (olaparib) for Patients With Metastatic Squamous Non-Small Cell Lung Cancer to Stop for Futility
2023-12-07 11:00 ET
Merck Announces Findings from Phase 2 KeyVibe-002 Trial Evaluating an Investigational Coformulation of Vibostolimab and Pembrolizumab in Previously Treated Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC)
2023-11-30 22:00 ET
FDA Grants Priority Review to Merck’s Application for KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) for the First-Line Treatment of Patients With Locally Advanced or Metastatic Urothelial Cancer
2023-11-28 18:17 ET
Merck Announces First-Quarter 2024 Dividend
2023-11-28 11:45 ET
Merck’s V116, an Investigational, 21-valent Pneumococcal Conjugate Vaccine Specifically Designed to Protect Adults, Demonstrated Superior Immunogenicity for 10 of 11 Unique Serotypes Compared to PCV20 in Adults 50 Years of Age and Older
2023-11-21 11:45 ET
Merck to Acquire Caraway Therapeutics, Inc.
2023-11-20 11:45 ET
Merck to Participate in the 6th Annual Evercore ISI HealthCONx Conference
2023-11-16 22:40 ET
FDA Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy as First-Line Treatment for Locally Advanced Unresectable or Metastatic HER2-Negative Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
2023-11-10 12:40 ET
Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) Plus Gemcitabine and Cisplatin as First-Line Treatment for Locally Advanced Unresectable or Metastatic Biliary Tract Cancer
2023-11-08 11:45 ET
Merck to Participate in the Jefferies London Healthcare Conference
2023-11-01 10:50 ET
Merck to Participate in the UBS BioPharma Conference
2023-11-01 10:45 ET
FDA Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Gemcitabine and Cisplatin as Treatment for Patients With Locally Advanced Unresectable or Metastatic Biliary Tract Cancer
2023-11-01 10:30 ET
KEYTRUDA® (pembrolizumab) Significantly Improved Overall Survival (OS) Versus Placebo as Adjuvant Therapy for Certain Patients With Renal Cell Carcinoma (RCC) Following Nephrectomy
2023-10-26 10:30 ET
Merck Announces Third-Quarter 2023 Financial Results
2023-10-22 14:30 ET
KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) Reduced Risk of Death by More Than Half Versus Chemotherapy in Patients With Previously Untreated Locally Advanced or Metastatic Urothelial Cancer
2023-10-21 12:45 ET
Merck’s WELIREG® (belzutifan) Significantly Improved Progression-Free Survival and Objective Response Rates Versus Everolimus in Certain Previously Treated Patients With Advanced Renal Cell Carcinoma (RCC)
2023-10-20 14:00 ET
Merck’s KEYTRUDA® (pembrolizumab) Plus Concurrent Chemoradiotherapy Significantly Improved Progression-Free Survival (PFS) Versus Concurrent Chemoradiotherapy Alone in Newly Diagnosed, High-Risk Locally Advanced Cervical Cancer
2023-10-20 12:02 ET
Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy Showed Statistically Significant Improvement in Pathological Complete Response (pCR) Rate as Neoadjuvant Therapy Versus Chemotherapy in High-Risk, Early-Stage ER+/HER2- Breast Cancer
2023-10-20 12:01 ET
KEYTRUDA® (pembrolizumab) Plus Trastuzumab and Chemotherapy Significantly Improved Progression-Free Survival (PFS) Versus Trastuzumab and Chemotherapy in First-Line HER2-Positive Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
2023-10-20 12:00 ET
KEYTRUDA® (pembrolizumab) Plus Chemotherapy Before Surgery and Continued as Single Agent After Surgery Reduced Risk of Death by 28% Versus Pre-Operative Chemotherapy in Resectable Stage II, IIIA or IIIB Non-Small Cell Lung Cancer (NSCLC)
2023-10-19 23:30 ET
Daiichi Sankyo and Merck Announce Global Development and Commercialization Collaboration for Three Daiichi Sankyo DXd ADCs
2023-10-17 10:45 ET
Merck Receives Positive EU CHMP Opinion for PREVYMIS® for Prevention of CMV Disease in High-Risk Adult Kidney Transplant Recipients and Extended 200-Day Dosing in Adult HSCT Recipients at Risk for Late CMV Infection and Disease
2023-10-16 23:00 ET
FDA Approves KEYTRUDA® (pembrolizumab) for Treatment of Patients With Resectable (T≥4 cm or N+) NSCLC in Combination With Chemotherapy as Neoadjuvant Treatment, Then Continued as a Single Agent as Adjuvant Treatment After Surgery
2023-10-16 10:45 ET
European Commission Approves KEYTRUDA® (pembrolizumab) as Adjuvant Treatment for Adults With Non-Small Cell Lung Cancer at High Risk of Recurrence Following Complete Resection and Platinum-Based Chemotherapy
2023-10-13 11:45 ET
Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) Plus Chemotherapy as First-Line Treatment for HER2-Negative Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma Expressing PD-L1 (CPS ≥1)
2023-10-10 10:45 ET
Merck Highlights Innovative Oncology Portfolio and Pipeline at ESMO Congress 2023 Underscoring Commitment to Advancing Cancer Research and Improving Patient Outcomes Across Multiple Stages of Disease
2023-10-10 10:30 ET
Merck Announces Pivotal KEYNOTE-671 Trial Meets Dual Primary Endpoint of Overall Survival (OS) in Resectable Stage II, IIIA or IIIB Non-Small Cell Lung Cancer (NSCLC)
2023-10-05 11:00 ET
Merck’s KEYTRUDA® (pembrolizumab) Met Primary Endpoint of Disease-Free Survival (DFS) in Certain Patients With Muscle-Invasive Urothelial Carcinoma (MIUC) After Surgery
2023-10-05 10:45 ET
Merck to Hold Third-Quarter 2023 Sales and Earnings Conference Call Oct. 26
2023-09-28 10:45 ET
Merck Receives Priority Review from FDA for New Biologics License Application for Sotatercept, an Activin Signaling Inhibitor to Treat Adults with Pulmonary Arterial Hypertension (PAH)
2023-09-22 10:45 ET
Merck and Eisai Provide Update on Two Phase 3 Trials Evaluating KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) in Patients With Certain Types of Metastatic Non-Small Cell Lung Cancer
2023-09-22 10:00 ET
Merck Announces Phase 3 KEYNOTE-A39/EV-302 Trial Met Dual Primary Endpoints of Overall Survival (OS) and Progression-Free Survival (PFS) in Certain Patients With Previously Untreated Locally Advanced or Metastatic Urothelial Cancer
2023-09-20 10:45 ET
FDA Grants Priority Review to Merck’s Application for KEYTRUDA® (pembrolizumab) Plus Concurrent Chemoradiotherapy as Treatment for Patients With Newly Diagnosed High-Risk Locally Advanced Cervical Cancer
2023-09-19 10:45 ET
FDA Accepts for Priority Review Merck’s Supplemental New Drug Application for WELIREG® (belzutifan) in Certain Previously Treated Patients With Advanced Renal Cell Carcinoma (RCC)
2023-09-15 13:10 ET
Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) as Adjuvant Treatment for Adults with Non-Small Cell Lung Cancer at High Risk of Recurrence Following Complete Resection and Platinum-Based Chemotherapy
2023-09-11 11:45 ET
Merck Presents New Analyses Supporting the Promising Potential of Sotatercept, its Investigational Medicine for Adults with Pulmonary Arterial Hypertension (PAH)
2023-09-07 10:45 ET
European Commission Expands Merck’s ERVEBO® [Ebola Zaire Vaccine, (rVSVΔG-ZEBOV-GP) live] Indication to Include Children 1 Year of Age and Older
2023-09-05 12:00 ET
Long-Term Follow-up Data on Sustained Immunogenicity and Safety for GARDASIL®9 Published in Pediatrics
2023-09-05 10:45 ET
Merck to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference
2023-08-29 10:50 ET
European Commission Approves KEYTRUDA® (pembrolizumab) Plus Trastuzumab and Chemotherapy as First-Line Treatment for HER2-Positive Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma Expressing PD-L1 (CPS ≥1)
2023-08-29 10:45 ET
Merck to Participate in the Citi 18th Annual BioPharma Conference
2023-08-25 10:30 ET
Merck Initiates Phase 3 Clinical Program for Oral PCSK9 Inhibitor Candidate MK-0616
2023-08-25 10:15 ET
Merck and Eisai Provide Update on Phase 3 LEAP-010 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) in Patients With Certain Types of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
2023-08-24 10:45 ET
LYNPARZA® (olaparib) Plus Abiraterone and Prednisone or Prednisolone Approved in Japan for the Treatment of BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer
2023-08-18 10:45 ET
Merck Announces WELIREG® (belzutifan) Phase 3 LITESPARK-005 Trial Met Primary Endpoint of Progression-Free Survival in Certain Previously Treated Patients With Advanced Renal Cell Carcinoma
2023-08-03 10:45 ET
U.S. FDA Approves Merck’s ERVEBO® (Ebola Zaire Vaccine, Live) for Use in Children 12 Months of Age and Older
2023-08-01 10:30 ET
Merck Announces Second-Quarter 2023 Financial Results
2023-07-28 10:45 ET
Merck Announces Phase 3 KEYNOTE-756 Trial Met Primary Endpoint of Pathological Complete Response (pCR) Rate in Patients With High-Risk, Early-Stage ER+/HER2- Breast Cancer
2023-07-27 10:45 ET
Merck Announces V116, an Investigational, 21-valent Pneumococcal Conjugate Vaccine Specifically Designed for Adults, Met Key Immunogenicity and Safety Endpoints in Two Phase 3 Trials
2023-07-25 16:58 ET
Merck Announces Fourth-Quarter 2023 Dividend
2023-07-21 11:52 ET
Merck Receives Positive European Union CHMP Opinion for Gefapixant
2023-07-21 11:50 ET
Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) Plus Trastuzumab and Chemotherapy as First-Line Treatment for HER2-Positive Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma Expressing PD-L1 (CPS ≥1)
2023-07-19 10:45 ET
Merck Announces Phase 3 KEYNOTE-A18 Trial Met Primary Endpoint of Progression-Free Survival (PFS) in Patients With Newly Diagnosed High-Risk Locally Advanced Cervical Cancer
2023-06-29 10:45 ET
Merck to Hold Second-Quarter 2023 Sales and Earnings Conference Call on Aug. 1
2023-06-20 10:45 ET
Merck Provides Update on Phase 3 KEYNOTE-585 Trial in Locally Advanced Resectable Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma
2023-06-16 10:45 ET
KEYTRUDA® (pembrolizumab) Plus Trastuzumab and Chemotherapy Met Primary Endpoint of Progression-Free Survival as First-Line Treatment in Patients With HER2-Positive Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
2023-06-13 20:05 ET
U.S. District Court for the District of New Jersey Rules in Favor of Merck in Patent Infringement Lawsuit Related to BRIDION® (sugammadex)
2023-06-12 10:45 ET
Merck to Present Data for Efinopegdutide (MK-6024), an Investigational GLP-1/Glucagon Receptor Co-agonist, in Patients with Nonalcoholic Fatty Liver Disease (NAFLD) at EASL 2023
2023-06-08 10:45 ET
FDA Accepts Application for Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy as Treatment for Advanced or Unresectable Biliary Tract Cancer
2023-06-06 10:50 ET
U.S. FDA Approves New Indication for Merck’s PREVYMIS® (letermovir) for Prevention of Cytomegalovirus (CMV) Disease in High-Risk Adult Kidney Transplant Recipients
2023-06-06 10:45 ET
Merck to Participate in the Goldman Sachs 44th Annual Global Healthcare Conference
2023-06-03 13:00 ET
Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy Before Surgery and Continued as a Single Agent After Surgery Reduced the Risk of Event-Free Survival Events by 42% Versus Pre-Operative Chemotherapy in Resectable Stage II, IIIA or IIIB NSCLC
2023-06-03 12:00 ET
KEYTRUDA® (pembrolizumab) Plus Chemotherapy Significantly Improved Overall Survival Versus Chemotherapy Alone as First-Line Treatment for Unresectable Advanced Pleural Mesothelioma
2023-06-01 10:45 ET
FDA Approves LYNPARZA® (olaparib) Plus Abiraterone and Prednisone or Prednisolone for Treatment of Adult Patients With BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer (mCRPC)
2023-05-25 21:00 ET
KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Demonstrates Long-Term, Durable Survival Benefit Versus Sunitinib as First-Line Treatment for Patients With Advanced Renal Cell Carcinoma
2023-05-23 18:45 ET
Merck Announces Third-Quarter 2023 Dividend
2023-05-15 10:45 ET
Merck to Present Extensive New Research Demonstrating Significant Progress in the Treatment of Certain Earlier Stage Cancers and in Advancing Broad Oncology Pipeline at 2023 ASCO Annual Meeting
2023-05-03 10:45 ET
Merck to Participate in Bank of America Securities 2023 Healthcare Conference
2023-04-28 21:30 ET
Update on FDA Advisory Committee Vote on LYNPARZA® (olaparib) Plus Abiraterone and Prednisone or Prednisolone in First-Line Metastatic Castration-Resistant Prostate Cancer
2023-04-27 10:30 ET
Merck Announces First-Quarter 2023 Financial Results
2023-04-16 15:00 ET
Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy Significantly Improved Overall Survival Compared to Chemotherapy Alone in Patients With Advanced or Unresectable Biliary Tract Cancer
2023-04-13 10:45 ET
FDA Accepts Application for Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy as First-Line Treatment for Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
2023-04-07 10:45 ET
Merck and Eisai Provide Update on Phase 3 Trials of KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) In Certain Patients With Advanced Melanoma (LEAP-003) and Metastatic Colorectal Cancer (LEAP-017)
2023-04-03 21:00 ET
FDA Approves Merck’s KEYTRUDA® (pembrolizumab) in Combination With Padcev® (enfortumab vedotin-ejfv) for First-Line Treatment of Certain Patients With Locally Advanced or Metastatic Urothelial Cancer
2023-03-30 10:45 ET
Merck to Hold First-Quarter 2023 Sales and Earnings Conference Call on April 27
2023-03-29 20:15 ET
FDA Converts to Full Approval Indication for KEYTRUDA® (pembrolizumab) for Certain Adult and Pediatric Patients With Advanced Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Solid Tumors
2023-03-27 21:15 ET
KEYTRUDA® (pembrolizumab) Plus Chemotherapy Significantly Improved Progression-Free Survival Compared to Chemotherapy Alone as First-Line Therapy for Advanced or Recurrent Endometrial Carcinoma, Regardless of Mismatch Repair Status
2023-03-16 20:05 ET
Merck Provides Update from Open-Label Arm of Phase 2 KeyVibe-002 Trial Evaluating MK-7684A, a Coformulation of Vibostolimab and Pembrolizumab, in Previously Treated Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC)
2023-03-10 11:45 ET
KEYTRUDA® (pembrolizumab) Plus Chemotherapy Significantly Improved Overall Survival Versus Chemotherapy Alone as First-Line Treatment for Advanced Malignant Pleural Mesothelioma
2023-03-08 11:45 ET
Merck to Present at the Barclays 2023 Global Healthcare Conference
2023-03-06 17:01 ET
Merck’s Investigational Activin Signaling Inhibitor Sotatercept Improved Six-Minute Walk Distance by 40.8 Meters at Week 24 Versus Placebo in Adults with Pulmonary Arterial Hypertension on Background Therapy
2023-03-06 17:00 ET
Merck’s MK-0616, an Investigational Oral PCSK9 Inhibitor, Significantly Reduced LDL-C in Patients with Hypercholesterolemia in Phase 2b Study
2023-03-06 11:45 ET
US FDA Approves Intramuscular Administration for Merck’s MMRV Family of Vaccines: M-M-RII (Measles, Mumps, and Rubella Virus Vaccine Live), VARIVAX (Varicella Virus Vaccine Live), and ProQuad (Measles, Mumps, Rubella and Varicella Virus Vaccine Live)
2023-03-02 14:00 ET
Merck and AstraZeneca Provide Update on US Regulatory Review of LYNPARZA® (olaparib) for Use in Combination With Abiraterone and Prednisone or Prednisolone for the Treatment of Metastatic Castration-Resistant Prostate Cancer
2023-03-01 11:45 ET
Merck Announces Phase 3 KEYNOTE-671 Trial Met Primary Endpoint of Event-Free Survival (EFS) in Patients With Resectable Stage II, IIIA or IIIB Non-Small Cell Lung Cancer
2023-02-28 11:45 ET
Merck Provides Update on Phase 3 Trials KEYNOTE-641 and KEYNOTE-789
2023-02-24 11:49 ET
Merck and Ridgeback Provide Update on EU Marketing Authorization Application for LAGEVRIO™ (Molnupiravir)
2023-02-22 11:45 ET
Merck Opens Enrollment in New Phase 3 Clinical Trials with Investigational Once-Daily Islatravir in Combination with Doravirine for Treatment of HIV-1 Infection
2023-02-21 11:45 ET
Merck to Present New Data for Sotatercept and MK-0616 at ACC.23/WCC, Demonstrating Significant Progress in Advancing Its Innovative Cardiovascular Pipeline
2023-02-21 11:40 ET
Merck Provides Update on Phase 3 MOVe-AHEAD Trial Evaluating LAGEVRIO™ (molnupiravir) for Post-exposure Prophylaxis for Prevention of COVID-19
2023-02-17 11:45 ET
U.S. FDA Accepts for Priority Review the Supplemental New Drug Application for Merck’s PREVYMIS™ for Prophylaxis of Cytomegalovirus Disease in Kidney Transplant Recipients at High Risk
2023-02-16 17:30 ET
Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy Significantly Improved Overall Survival Versus Chemotherapy Alone in Patients With HER2-Negative Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma Regardless of PD-L1 Expression
2023-02-16 15:00 ET
Merck and AstraZeneca Present Final Results of Key Secondary Overall Survival Endpoint From Phase 3 PROpel Trial at 2023 American Society of Clinical Oncology Genitourinary Cancers Symposium
2023-02-03 11:45 ET
Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy Met Primary Endpoint of Progression-Free Survival (PFS) as First-Line Therapy for Advanced or Recurrent Endometrial Carcinoma
2023-02-02 11:30 ET
Merck Announces Fourth-Quarter and Full-Year 2022 Financial Results
2023-01-27 11:45 ET
FDA Approves KEYTRUDA® (pembrolizumab) as Adjuvant Treatment Following Surgical Resection and Platinum-Based Chemotherapy for Patients With Stage IB (T2a ≥4 Centimeters), II, or IIIA Non-Small Cell Lung Cancer (NSCLC)
2023-01-26 13:02 ET
Merck Animal Health Receives U.S. FDA Approval of Expanded Indication for BRAVECTO (fluralaner) Chews for Dogs
2023-01-25 11:50 ET
Merck Announces KEYNOTE-991 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus Enzalutamide and Androgen Deprivation Therapy in Patients With Metastatic Hormone-Sensitive Prostate Cancer to Stop for Futility
2023-01-25 11:45 ET
Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy Significantly Improved Overall Survival Versus Chemotherapy in First-Line Advanced or Unresectable Biliary Tract Cancer in KEYNOTE-966 Trial
2023-01-24 18:19 ET
Merck Announces Second-Quarter 2023 Dividend
2023-01-18 03:58 ET
Merck Selects Perceiv AI for Inaugural Digital Sciences Studio Cohort
2023-01-10 14:00 ET
Merck Named One of America’s Most JUST Companies by JUST Capital and CNBC, Industry Leader in Pharmaceuticals and Biotech
2023-01-05 11:45 ET
Merck to Hold Fourth-Quarter and Full-Year 2022 Sales and Earnings Conference Call February 2
2023-01-03 11:45 ET
Merck to Present at the 41st Annual J.P. Morgan Healthcare Conference
2022-12-22 12:00 ET
Merck to Present at the Goldman Sachs Healthcare CEOs Unscripted Conference
2022-12-22 11:45 ET
Merck and Kelun-Biotech Announce Exclusive License and Collaboration Agreement for Seven Investigational Antibody-drug Conjugate Candidates for the Treatment of Cancer
2022-12-21 11:45 ET
LYNPARZA® (olaparib) in Combination With Abiraterone and Prednisone or Prednisolone Approved in the EU as Treatment for Certain Patients With Metastatic Castration-Resistant Prostate Cancer
2022-12-15 11:45 ET
AstraZeneca and Merck Provide Update on US Regulatory Review of LYNPARZA® (olaparib) in Combination With Abiraterone and Prednisone or Prednisolone as Treatment of Metastatic Castration-Resistant Prostate Cancer
2022-12-01 11:45 ET
Merck to Present Data From Its Hematology Portfolio and Promising Pipeline at the 64th American Society of Hematology (ASH) Annual Meeting
2022-11-29 16:41 ET
Merck Announces First-Quarter 2023 Dividend
2022-11-22 11:45 ET
Merck Announces Phase 3 KEYNOTE-859 Trial Met Primary Endpoint of Overall Survival in Patients With HER2-Negative Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
2022-11-21 11:45 ET
Merck to Present at the 5th Annual Evercore ISI HealthCONx Conference
2022-11-14 11:45 ET
LYNPARZA® (olaparib) in Combination With Abiraterone and Prednisone or Prednisolone Receives Positive Opinion From EU CHMP as Treatment for Certain Patients With Metastatic Castration-Resistant Prostate Cancer
2022-11-09 15:40 ET
Our Partnerships Help Make Vaccines Accessible Worldwide
2022-11-07 11:45 ET
Reductions in Certain Types of HPV-Related Cervical and Non-Cervical Diseases in Women and Men Observed with Real-World Use of Merck's GARDASIL® in Systematic Literature Review of 138 Studies
2022-11-02 13:00 ET
Dedicated To Developing Women Leaders
2022-11-01 11:03 ET
Veeva and Merck Form Long-Term Strategic Partnership
2022-10-27 10:30 ET
Merck Announces Third-Quarter 2022 Financial Results
2022-10-26 21:00 ET
Robert M. Davis to Succeed Kenneth C. Frazier as Chairman of Merck
2022-10-24 10:45 ET
European Commission Expands Merck’s VAXNEUVANCE™ (Pneumococcal 15-valent Conjugate Vaccine) Indication to Include Infants, Children and Adolescents
2022-10-22 19:00 ET
Merck’s PREVYMIS™ Demonstrates Efficacy in Phase 3 Study for Prevention of Cytomegalovirus Disease in Adults After Kidney Transplantation
2022-10-18 13:07 ET
Merck Animal Health Launches Sure Petcare Animo® GPS
2022-10-18 10:45 ET
Merck and the Bill & Melinda Gates Medical Research Institute Announce Licensing Agreement for Novel Tuberculosis Antibiotic Candidates
2022-10-10 12:00 ET
Merck Recognized on Fortune’s 2022 Change the World List for Expanding Access to HPV Vaccines
2022-10-10 10:45 ET
Merck Announces Positive Top-line Results from Pivotal Phase 3 STELLAR Trial Evaluating Sotatercept for the Treatment of Adults with Pulmonary Arterial Hypertension (PAH)
2022-10-06 23:50 ET
Merck and Ridgeback Biotherapeutics Provide Update on New Clinical and Non-Clinical Studies of LAGEVRIO™ (molnupiravir)
2022-09-29 19:22 ET
U.S. Court of Appeals for the Federal Circuit Rules in Favor of Merck in Sitagliptin Dihydrogen Phosphate Patent Lawsuit
2022-09-29 10:45 ET
Merck to Hold Third-Quarter 2022 Sales and Earnings Conference Call October 27
2022-09-27 11:00 ET
Merck Animal Health Completes Minority Investment in LeeO Precision Farming
2022-09-27 10:45 ET
Merck’s KEYTRUDA® (pembrolizumab) Receives Four New Approvals in Japan, Including in High-Risk Early-Stage Triple-Negative Breast Cancer (TNBC)
2022-09-22 11:30 ET
Merck Animal Health to Acquire Vence
2022-09-22 10:45 ET
LYNPARZA® (olaparib) Approved in China as First-Line Maintenance Treatment With Bevacizumab for Homologous Recombination Deficient (HRD)-Positive Advanced Ovarian Cancer
2022-09-22 10:40 ET
U.S. District Court Rules In Favor of Merck in Sitagliptin Phosphate Patent Lawsuit
2022-09-20 10:45 ET
Merck to Initiate New Phase 3 Clinical Program with Lower Dose of Daily Oral Islatravir in Combination with Doravirine for Treatment of People with HIV-1 Infection
2022-09-16 11:30 ET
Merck Receives Positive CHMP Opinion for VAXNEUVANCE™ (Pneumococcal 15-valent Conjugate Vaccine) in Infants and Children
2022-09-12 05:37 ET
Eisai and Merck & Co., Inc. Present Results from Phase 3 LEAP-002 Trial Evaluating LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Versus LENVIMA Monotherapy in Patients With Unresectable Hepatocellular Carcinoma
2022-09-11 08:15 ET
Five-Year Data for Merck's KEYTRUDA® (pembrolizumab) Plus Chemotherapy Showed Sustained Survival Benefit Versus Chemotherapy Alone in Two Studies for Metastatic Non-Small Cell Lung Cancer (NSCLC)
2022-09-10 06:30 ET
Merck and Eisai Present Results From Phase 3 LEAP-002 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Versus LENVIMA Monotherapy in Patients With Unresectable Hepatocellular Carcinoma
2022-09-09 12:00 ET
LYNPARZA® (olaparib) in Combination With Bevacizumab, and as Monotherapy, Demonstrates Clinically Meaningful Long-Term Survival in Certain Patients With First-Line Advanced Ovarian Cancer in Exploratory Analyses of Two Phase 3 Trials
2022-09-08 14:00 ET
Merck Foundation Launches $20 Million Initiative to Advance Equity in U.S. Cancer Care
2022-09-06 10:45 ET
Merck to Present at the Morgan Stanley 20th Annual Global Healthcare Conference
2022-08-30 20:01 ET
Merck Reports Strong Progress in ESG Focus Areas
2022-08-29 10:45 ET
Merck to Present New Data at ESMO 2022 Congress From Its Broad Oncology Portfolio and Promising Pipeline, Demonstrating Commitment to Improving Long-Term Survival in Multiple Types of Cancer
2022-08-25 10:45 ET
LYNPARZA® (olaparib) Approved in Japan as Adjuvant Treatment for Patients With BRCA-Mutated, HER2-Negative High Recurrent Risk Breast Cancer
2022-08-23 10:45 ET
Merck Receives Fast Track Designation from the U.S. FDA for MK-2060, an Investigational Anticoagulant Therapy
2022-08-16 11:00 ET
FDA Accepts Submission of Supplemental New Drug Application for LYNPARZA® (olaparib) in Combination With Abiraterone and Prednisone or Prednisolone for Patients With Metastatic Castration-Resistant Prostate Cancer and Grants Priority Review
2022-08-16 10:45 ET
Merck and Orna Therapeutics Collaborate to Advance Orna’s Next Generation of RNA Technology
2022-08-04 10:45 ET
LYNPARZA® (olaparib) Approved in the EU as Adjuvant Treatment for Patients With Germline BRCA-Mutated, HER2-Negative High-Risk Early Breast Cancer
2022-08-03 10:45 ET
Merck and Eisai Provide Update on Phase 3 LEAP-002 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Versus LENVIMA Monotherapy in Patients With Unresectable Hepatocellular Carcinoma
2022-08-03 10:40 ET
Merck Provides Update on Phase 3 KEYNOTE-921 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus Chemotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer
2022-07-28 10:30 ET
Merck Announces Second-Quarter 2022 Financial Results
2022-07-26 16:40 ET
Merck Announces Fourth-Quarter 2022 Dividend
2022-07-20 10:45 ET
Merck Provides Update on Phase 3 KEYNOTE-412 Trial in Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma
2022-07-13 10:00 ET
Merck and Orion Announce Global Collaboration for the Development and Commercialization of ODM-208, an Investigational Steroid Synthesis Inhibitor for the Treatment of Metastatic Castration-Resistant Prostate Cancer
2022-06-29 11:00 ET
Merck Announces the Launch of the Merck Digital Sciences Studio to Help Healthcare Startups Quickly Bring their Innovations to Market
2022-06-29 10:45 ET
Merck to Hold Second-Quarter 2022 Sales and Earnings Conference Call July 28
2022-06-27 10:45 ET
LYNPARZA® (olaparib) Receives Positive Opinion From EU CHMP as Adjuvant Treatment for Germline BRCA-Mutated, HER2-Negative High-Risk Early Breast Cancer
2022-06-24 10:45 ET
European Commission Approves KEYTRUDA® (pembrolizumab) as Adjuvant Treatment for Adult and Adolescent Patients (≥12 Years of Age) With Stage IIB or IIC Melanoma Following Complete Resection
2022-06-22 22:28 ET
CDC’s ACIP Unanimously Votes to Provisionally Recommend Use of Merck’s VAXNEUVANCE™ (Pneumococcal 15-valent Conjugate Vaccine) as an Option for Pneumococcal Vaccination in Infants and Children
2022-06-22 10:45 ET
U.S. FDA Approves Merck’s VAXNEUVANCE™ (Pneumococcal 15-valent Conjugate Vaccine) for the Prevention of Invasive Pneumococcal Disease in Infants and Children
2022-06-21 20:30 ET
Results From Phase 3 PROpel Trial of LYNPARZA® (olaparib) Plus Abiraterone in First-Line Metastatic Castration-Resistant Prostate Cancer Published in NEJM Evidence
2022-06-21 20:10 ET
Merck Announces that Chirfi Guindo will Lead Marketing for Merck Human Health
2022-06-21 10:45 ET
Merck Presents Positive Results from Phase 1/2 Study Evaluating V116, the Company’s Investigational Pneumococcal Conjugate Vaccine for Adults
2022-06-13 10:45 ET
FDA Accepts Application for Merck’s KEYTRUDA® (pembrolizumab) as Adjuvant Therapy for Stage IB (≥4 centimeters)-IIIA Non-Small Cell Lung Cancer Following Complete Surgical Resection
2022-06-08 10:51 ET
Merck to Participate in the 2022 Goldman Sachs 43rd Annual Global Healthcare Conference
2022-06-07 10:45 ET
Merck and Ridgeback Announce New Data For Investigational LAGEVRIO™ (molnupiravir) From Phase 3 MOVe-OUT Study
2022-06-07 10:30 ET
Merck to Hold Investor Event to Highlight Oncology Portfolio and Pipeline
2022-06-05 12:00 ET
Adjuvant Treatment With Merck’s KEYTRUDA® (pembrolizumab) Demonstrates Statistically Significant & Clinically Meaningful Improvement in Distant Metastasis-Free Survival in Patients With Resected Stage IIB or IIC Melanoma in Phase 3 KEYNOTE-716 Trial
2022-05-24 17:46 ET
Merck Announces Third-Quarter 2022 Dividend
2022-05-24 10:45 ET
European Commission Approves KEYTRUDA® (pembrolizumab) Plus Chemotherapy as Neoadjuvant Treatment, Then Continued as Adjuvant Monotherapy After Surgery for Locally Advanced or Early-Stage Triple-Negative Breast Cancer at High Risk of Recurrence
2022-05-20 12:15 ET
Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) as Adjuvant Treatment for Adult and Adolescent (≥12 Years of Age) Patients With Stage IIB or IIC Melanoma Following Complete Resection
2022-05-10 10:45 ET
Merck To Present Data at 2022 ASCO Annual Meeting Highlighting Promising Pipeline Medicines and Significant Progress in Treating Earlier Stages of Certain Cancers With KEYTRUDA® (pembrolizumab)
2022-05-04 10:45 ET
Merck to Participate in Bank of America Securities 2022 Healthcare Conference
2022-04-29 10:45 ET
European Commission Approves Merck’s KEYTRUDA® (pembrolizumab) for Patients With Microsatellite Instability-High (MSI-H) or Deficient Mismatch Repair (dMMR) Tumors in Five Different Types of Cancer
2022-04-29 10:30 ET
European Commission Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy, With or Without Bevacizumab, for Patients With Persistent, Recurrent or Metastatic Cervical Cancer Whose Tumors Express PD-L1 (CPS ≥1)
2022-04-28 10:30 ET
Merck Announces First-Quarter 2022 Financial Results
2022-04-25 10:45 ET
Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) Plus Chemotherapy as Neoadjuvant Treatment, Then Continued as Adjuvant Monotherapy After Surgery for Locally Advanced, or High-Risk Early-Stage Triple-Negative Breast Cancer (TNBC)
2022-04-20 10:45 ET
Merck Announces That Joseph Romanelli Will Lead Merck Human Health International, Effective August 1, 2022
2022-04-14 10:45 ET
Merck Announces U.S. FDA has Granted Breakthrough Therapy Designation for V116, the Company’s Investigational 21-Valent Pneumococcal Conjugate Vaccine, for the Prevention of Invasive Pneumococcal Disease and Pneumococcal Pneumonia in Adults
2022-04-08 10:45 ET
Merck to Hold First-Quarter 2022 Sales and Earnings Conference Call April 28
2022-04-05 10:45 ET
Merck Investor Event Today Will Highlight Broad and Growing Cardiovascular Portfolio and Pipeline in Areas of Unmet Patient Need
2022-04-04 10:45 ET
Expansion of Elkton, Virginia Manufacturing Facility to Further Increase Merck’s HPV Vaccine Supply and Support Broader and Equitable Access
2022-04-01 10:45 ET
Merck Provides Update on FDA Review of Supplemental Biologics License Application for VAXNEUVANCE™ (Pneumococcal 15-valent Conjugate Vaccine) for Use in Infants and Children
2022-04-01 10:40 ET
Merck and Ridgeback to Present Data Demonstrating That Treatment With LAGEVRIO™ (molnupiravir) Was Associated With More Rapid Elimination of Infectious SARS-CoV-2 Than Placebo
2022-03-31 11:30 ET
Eikon Therapeutics Announces the Election of Kenneth C. Frazier to Its Board of Directors
2022-03-25 13:00 ET
Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) for Patients With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Tumors in Five Different Types of Cancer
2022-03-25 12:56 ET
Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) Plus Chemotherapy, With or Without Bevacizumab, as Treatment for Patients With Persistent, Recurrent or Metastatic Cervical Cancer Whose Tumors Express PD-L1 (CPS ≥1)
2022-03-23 11:25 ET
Merck Announces Retirement of Dr. Roy D. Baynes; Dr. Eliav Barr Appointed Head of Global Clinical Development and Chief Medical Officer
2022-03-22 10:30 ET
Systematic Review and Meta-Analysis of Real-World Observational Studies Provide Additional Evidence of Effectiveness of PREVYMIS™ in Preventing Cytomegalovirus Infection and Disease in Adults Undergoing Allogeneic HCT
2022-03-21 20:30 ET
FDA Approves Merck’s KEYTRUDA® (pembrolizumab) for Patients With MSI‑H/dMMR Advanced Endometrial Carcinoma, Who Have Disease Progression Following Prior Systemic Therapy in Any Setting and Are Not Candidates for Curative Surgery or Radiation
2022-03-17 18:15 ET
Merck’s KEYTRUDA® (pembrolizumab) Significantly Improved Disease-Free Survival (DFS) Versus Placebo as Adjuvant Therapy in Patients With Stage IB-IIIA Non-Small Cell Lung Cancer (NSCLC) Regardless of PD-L1 Expression
2022-03-16 17:30 ET
LYNPARZA® (olaparib) Reduced Risk of Death by 32% in Patients With Germline BRCA-Mutated, HER2-Negative High-Risk Early Breast Cancer in Phase 3 OlympiA Trial
2022-03-15 10:45 ET
Merck Announces KEYLYNK-010 Trial Evaluating KEYTRUDA® (pembrolizumab) in Combination with LYNPARZA® (olaparib) in Patients with Metastatic Castration-Resistant Prostate Cancer to Stop for Futility
2022-03-12 00:51 ET
FDA Approves LYNPARZA® (olaparib) as Adjuvant Treatment for Patients With Germline BRCA-Mutated (gBRCAm), HER2-Negative High-Risk Early Breast Cancer Who Have Been Treated With Neoadjuvant or Adjuvant Chemotherapy
2022-03-07 11:45 ET
Merck’s KEYTRUDA® (pembrolizumab) Demonstrated Significant Improvement in Distant Metastasis-Free Survival (DMFS) Compared to Placebo as Adjuvant Therapy for Patients With Resected Stage IIB and IIC Melanoma in Phase 3 KEYNOTE-716 Trial
2022-03-07 11:45 ET
Merck to Hold Investor Event to Highlight Growing Cardiovascular Portfolio and Pipeline
2022-03-04 11:45 ET
Merck to Participate in Cowen’s 42nd Annual Health Care Conference
2022-03-01 15:15 ET
Dr. Julie L. Gerberding to Retire from Merck
2022-02-25 11:45 ET
KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Approved in Japan for Radically Unresectable or Metastatic Renal Cell Carcinoma
2022-02-23 11:45 ET
Merck Shares Environmental, Social & Governance Priorities and Strategy
2022-02-16 13:30 ET
Organon Acquires Contraceptive Products, Marvelon® and Mercilon®, in the People’s Republic of China, including Hong Kong and Macau, and Agrees to Acquire these Products in Vietnam
2022-02-16 11:45 ET
Merck Announces New Leadership for Human Health Business
2022-02-14 22:00 ET
LYNPARZA® (olaparib) Plus Abiraterone Reduced Risk of Disease Progression or Death by 34% Versus Abiraterone in First-Line Metastatic Castration-Resistant Prostate Cancer, Regardless of Biomarker Status
2022-02-14 11:45 ET
Merck to Hold Event to Discuss Long-Term Environmental, Social & Governance Priorities
2022-02-10 11:45 ET
Merck to Participate in the 11th Annual SVB Leerink Global Healthcare Conference
2022-02-09 22:00 ET
Pivotal Phase 3 Data for KEYTRUDA® (pembrolizumab) in High-Risk Early-Stage Triple-Negative Breast Cancer (TNBC) Published in the New England Journal of Medicine
2022-02-08 11:45 ET
Merck and Ridgeback Announce That 3.1 Million Courses of Molnupiravir, an Investigational Oral Antiviral COVID-19 Medicine, Have Been Supplied to the U.S. Government for Use in the United States
2022-02-04 11:45 ET
Merck to Participate in the Guggenheim Oncology Conference 2022
2022-02-03 11:30 ET
Merck Announces Fourth-Quarter and Full-Year 2021 Financial Results
2022-01-28 11:45 ET
Merck and Ridgeback’s Molnupiravir, an Investigational Oral Antiviral COVID-19 Medicine, Demonstrated Activity Against Omicron Variant in In Vitro Studies
2022-01-27 11:45 ET
European Commission Approves Merck’s KEYTRUDA® (pembrolizumab) as Adjuvant Therapy for Certain Patients With Renal Cell Carcinoma (RCC) Following Surgery
2022-01-25 18:34 ET
Merck Announces Second-Quarter 2022 Dividend
2022-01-24 11:45 ET
Merck Provides U.S. and Japan Regulatory Update for Gefapixant
2022-01-20 11:50 ET
Results From Pivotal Phase 3 KEYNOTE-775/Study 309 Trial of KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) in Advanced Endometrial Carcinoma Published in the New England Journal of Medicine
2022-01-20 11:45 ET
Frank Clyburn to Leave Merck
2022-01-18 22:00 ET
Merck’s KEYTRUDA® (pembrolizumab) Significantly Improved Overall Survival (OS) Versus Placebo in Certain Patients With Advanced Hepatocellular Carcinoma (HCC) Previously Treated With Sorafenib
2022-01-18 13:02 ET
Merck Animal Health's Third Veterinarian Wellbeing Study Reveals Increased Health Challenges and Psychological Distress Among Veterinarians
2022-01-18 11:45 ET
Merck and Ridgeback Announce Supply Agreement with UNICEF for Molnupiravir, an Investigational Oral Antiviral COVID-19 Medicine
2022-01-10 11:45 ET
Merck’s KEYTRUDA® (pembrolizumab) Showed Statistically Significant Improvement in Disease-Free Survival Versus Placebo as Adjuvant Treatment for Patients With Stage IB-IIIA Non-Small Cell Lung Cancer Regardless of PD-L1 Expression
2022-01-07 21:30 ET
Merck to Hold Fourth-Quarter and Full-Year 2021 Sales and Earnings Conference Call on February 3
2022-01-04 22:00 ET
Merck to Present at the 40th Annual J.P. Morgan Healthcare Conference
2022-01-04 13:00 ET
Vaccinex Reports Phase Ib KEYNOTE B84 Combination Study of Keytruda® and Pepinemab in Patients with Advanced, Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) Passes Planned Interim Safety Analysis
2021-12-27 11:45 ET
KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Approved in Japan for Patients With Unresectable, Advanced or Recurrent Endometrial Carcinoma That Progressed After Cancer Chemotherapy
2021-12-24 11:45 ET
Merck and Ridgeback’s Molnupiravir, an Investigational Oral Antiviral COVID-19 Treatment, Receives Special Approval for Emergency in Japan
2021-12-23 16:08 ET
Merck and Ridgeback’s Molnupiravir Receives U.S. FDA Emergency Use Authorization for the Treatment of High-Risk Adults With Mild to Moderate COVID-19
2021-12-22 11:00 ET
Merck and Ridgeback Announce U.K. Government to Purchase Additional 1.75 Million Courses of Molnupiravir
2021-12-17 11:45 ET
Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) as Adjuvant Therapy for Certain Patients With Renal Cell Carcinoma Following Surgery
2021-12-16 22:19 ET
Merck and Ridgeback Announce Publication of Phase 3 Study of Molnupiravir, an Investigational Oral Antiviral COVID-19 Treatment, in the New England Journal of Medicine
2021-12-15 11:45 ET
ADDING and REPLACING European Commission Approves Merck’s VAXNEUVANCE™ (Pneumococcal 15-valent Conjugate Vaccine) for Individuals 18 Years of Age and Older
2021-12-13 22:00 ET
Merck Announces Clinical Holds on Studies Evaluating Islatravir for the Treatment and Prevention of HIV-1 Infection
2021-12-13 11:45 ET
Merck Issues $1 Billion Inaugural Sustainability Bond
2021-12-08 00:18 ET
Merck Prices $8.0 Billion Debt Offering
2021-12-07 11:15 ET
Merck Announces Additional $150M Investment Through 2025 to Help End Maternal Mortality Inequities
2021-12-06 22:00 ET
Merck Announces Pause in Enrollment for Two Phase 3 Clinical Trials of Investigational, Once-Monthly, Oral Islatravir for Pre-Exposure Prophylaxis (PrEP) of HIV-1 infection
2021-12-03 23:15 ET
FDA Approves Merck’s KEYTRUDA® (pembrolizumab) as Adjuvant Treatment for Adult and Pediatric (≥12 Years of Age) Patients With Stage IIB or IIC Melanoma Following Complete Resection
2021-12-01 11:45 ET
U.S. FDA Accepts for Priority Review the Supplemental Biologics License Application for Merck’s VAXNEUVANCE™ (Pneumococcal 15-valent Conjugate Vaccine) for Use in Infants and Children
2021-11-30 22:51 ET
Merck and Ridgeback Statement on Positive FDA Advisory Committee Vote for Investigational Oral Antiviral Molnupiravir for Treatment of Mild to Moderate COVID-19 in High Risk Adults
2021-11-30 19:48 ET
Merck Announces First-Quarter 2022 Dividend
2021-11-30 11:45 ET
Merck’s KEYTRUDA® (pembrolizumab) Approved in Japan in Combination With Chemotherapy for First-Line Treatment of Patients With Radically Unresectable, Advanced or Recurrent Esophageal Carcinoma
2021-11-30 11:30 ET
FDA Accepts Regulatory Submission of Supplemental New Drug Application for LYNPARZA® (olaparib) as Adjuvant Treatment in BRCA-Mutated, HER2-Negative High-Risk Early Breast Cancer and Grants Priority Review
2021-11-29 11:50 ET
European Commission Approves KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) for Patients With Certain Types of Endometrial Carcinoma
2021-11-29 11:45 ET
European Commission Approves KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) as First-Line Treatment for Adult Patients With Advanced Renal Cell Carcinoma
2021-11-26 11:45 ET
Merck and Ridgeback Biotherapeutics Provide Update on Results from MOVe-OUT Study of Molnupiravir, an Investigational Oral Antiviral Medicine, in At Risk Adults With Mild-to-Moderate COVID-19
2021-11-24 11:45 ET
Merck to Present at the 4th Annual Evercore ISI HealthCONx Conference
2021-11-22 11:45 ET
Merck Completes Acquisition of Acceleron Pharma Inc.
2021-11-19 23:06 ET
Merck Completes Tender Offer to Acquire Acceleron Pharma Inc.
2021-11-18 22:57 ET
Merck Provides Update on Phase 2 Clinical Trial of Once-Weekly Investigational Combination of MK-8507 and Islatravir for the Treatment of People Living with HIV-1
2021-11-18 11:45 ET
FDA Approves Merck’s KEYTRUDA® (pembrolizumab) as Adjuvant Therapy for Certain Patients With Renal Cell Carcinoma (RCC) Following Surgery
2021-11-17 19:26 ET
Avoro Capital Urges Acceleron Shareholders Not to Tender Into Merck’s Inadequate Offer
2021-11-17 11:45 ET
Merck Announces Expiration of Hart-Scott-Rodino Act Waiting Period and Extension of Tender Offer to Acquire Acceleron Pharma Inc.
2021-11-17 11:00 ET
Merck and Ridgeback to Present Phase 3 Data for Molnupiravir, an Investigational Oral COVID-19 Antiviral Medicine, at American Society of Tropical Medicine and Hygiene (ASTMH) 2021 Annual Meeting
2021-11-11 11:45 ET
Merck Announces Initiation of Phase 3 Study Evaluating VERQUVO® (vericiguat) in Patients with Chronic Heart Failure and Reduced Ejection Fraction Who Have Not Had a Recent Worsening Heart Failure Event
2021-11-10 13:00 ET
Merck and Ridgeback Announce Japanese Government to Purchase 1.6 Million Courses of Molnupiravir, an Investigational Oral COVID-19 Antiviral Medicine, Upon Authorization or Approval
2021-11-09 22:31 ET
Avoro Capital Releases Presentation Detailing Why Acceleron Shareholders Should Not Tender Into Merck’s Inadequate Offer
2021-11-09 11:00 ET
Merck and Ridgeback Announce U.S. Government to Purchase 1.4 Million Additional Courses of Molnupiravir, an Investigational Oral Antiviral Medicine, for the Treatment of Mild-to-Moderate COVID-19 in At Risk Adults
2021-11-08 21:30 ET
Merck Announces Receipt of Antitrust Clearance in Germany and Austria Relating to Tender Offer to Acquire Acceleron Pharma Inc.
2021-11-04 10:40 ET
Merck and Ridgeback’s Molnupiravir, an Oral COVID-19 Antiviral Medicine, Receives First Authorization in the World
2021-10-31 17:35 ET
New Research for KEYTRUDA® (pembrolizumab) at Society for Melanoma Research (SMR) 2021 Congress Reinforces Merck’s Commitment to Patients With Melanoma Across Stages of Disease
2021-10-29 20:34 ET
Merck Announces Withdrawal and Refiling under the Hart-Scott-Rodino Act and Extension of Tender Offer to Acquire Acceleron Pharma Inc.
2021-10-28 12:00 ET
Avoro Capital Issues Open Letter to Fellow Acceleron Pharma Shareholders
2021-10-28 10:30 ET
Merck Announces Third-Quarter 2021 Financial Results
2021-10-27 10:45 ET
Merck Presents New Data from Ongoing Phase 2b Clinical Trial Evaluating Efficacy and Safety of Investigational Islatravir in Combination With Doravirine Through 144 Weeks for HIV-1 Treatment at EACS 2021
2021-10-27 10:00 ET
The Medicines Patent Pool (MPP) and Merck Enter Into License Agreement for Molnupiravir, an Investigational Oral Antiviral COVID-19 Medicine, to Increase Broad Access in Low- and Middle-Income Countries
2021-10-26 10:45 ET
Gilead and Merck Initiate Phase 2 Study Evaluating an Oral Weekly Combination Regimen of Investigational Lenacapavir and Investigational Islatravir for HIV-1 Treatment in Virologically Suppressed Adults
2021-10-25 10:45 ET
Merck Announces Positive Top-Line Results from Pivotal Phase 3 Trials Evaluating Investigational, Once-Daily Oral Fixed Dose Combination of Doravirine/Islatravir for the Treatment of People with HIV-1 Infection
2021-10-25 10:00 ET
Merck and Ridgeback Announce Initiation of a Rolling Review by the European Medicines Agency for Molnupiravir, an Investigational Oral Antiviral Medicine, for the Treatment of COVID-19 in Adults
2021-10-22 10:45 ET
European Commission Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy as Treatment for Certain Patients With Locally Recurrent Unresectable or Metastatic Triple-Negative Breast Cancer (TNBC)
2021-10-20 23:07 ET
CDC ACIP Unanimously Votes to Provisionally Recommend Merck’s VAXNEUVANCE™ (Pneumococcal 15-valent Conjugate Vaccine) in Series with PNEUMOVAX ® 23 (Pneumococcal Vaccine Polyvalent) as an Option for Pneumococcal Vaccination in Appropriate Adults
2021-10-20 12:00 ET
Darwin Global Urges Acceleron Shareholders Not to Tender Their Shares to Merck
2021-10-19 23:30 ET
Merck Issues Voluntary Nationwide Recall of CUBICIN® (daptomycin for injection) 500 mg, Lot 934778, Due to Presence of Particulate Matter Identified as Glass Particles
2021-10-15 11:20 ET
Merck and Eisai Receive Positive EU CHMP Opinions for KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) in Two Different Types of Cancer
2021-10-15 11:15 ET
Merck Receives Positive CHMP Opinion for VAXNEUVANCE™ (Pneumococcal 15-valent Conjugate Vaccine) in Individuals 18 Years of Age and Older
2021-10-13 19:30 ET
Holocene Advisors Believes Merck’s Proposed Offer of $180 Per Share for Acceleron Significantly Undervalues Company 
2021-10-13 18:45 ET
FDA Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy, With or Without Bevacizumab, as Treatment for Patients With Persistent, Recurrent or Metastatic Cervical Cancer Whose Tumors Express PD-L1 (CPS ≥1)
2021-10-12 10:45 ET
Merck Begins Tender Offer to Acquire Acceleron Pharma Inc.
2021-10-11 10:00 ET
Merck and Ridgeback Announce Submission of Emergency Use Authorization Application to the U.S. FDA for Molnupiravir, an Investigational Oral Antiviral Medicine, for the Treatment of Mild-to-Moderate COVID-19 in At Risk Adults
2021-10-05 12:30 ET
 Merck and Emmy-Nominated Actress Yvonne Orji Unveil Uncovering TNBC, Highlighting the Challenges Faced by Black Women Diagnosed with Triple-Negative Breast Cancer
2021-10-01 10:00 ET
Merck and Ridgeback’s Investigational Oral Antiviral Molnupiravir Reduced the Risk of Hospitalization or Death by Approximately 50 Percent Compared to Placebo for Patients with Mild or Moderate COVID-19 in Positive Interim Analysis of Phase 3 Study
2021-09-30 19:52 ET
Avoro Capital Believes Proposed Acquisition of Acceleron Pharma by Merck Undervalues Acceleron Pharma
2021-09-30 10:45 ET
Merck to Acquire Acceleron Pharma Inc.
2021-09-29 20:00 ET
Merck Announces Appointment of Thomas H. Glocer as Independent Lead Director
2021-09-28 10:45 ET
Merck to Hold Third-Quarter 2021 Sales and Earnings Conference Call on October 28
2021-09-27 10:45 ET
Merck Announces KEYTRUDA® (pembrolizumab) Met Primary Endpoint of Overall Survival (OS) in Patients with Advanced Hepatocellular Carcinoma Previously Treated with Sorafenib
2021-09-24 10:45 ET
LYNPARZA® (olaparib) in Combination With Abiraterone Significantly Delayed Disease Progression in Patients Regardless of Biomarker Status in PROpel Phase 3 Trial in First-Line Metastatic Castration-Resistant Prostate Cancer (mCRPC)
2021-09-19 11:30 ET
Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy Reduced Risk of Death by 27% Versus Chemotherapy as First-Line Treatment for Patients With Metastatic Triple-Negative Breast Cancer Whose Tumors Expressed PD-L1 (CPS ≥10)
2021-09-18 13:05 ET
Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy With or Without Bevacizumab Reduced Risk of Death by One-Third Versus Chemotherapy With or Without Bevacizumab as First-Line Treatment for Persistent, Recurrent or Metastatic Cervical Cancer
2021-09-18 13:05 ET
Merck’s KEYTRUDA® (pembrolizumab) Demonstrated Superior Recurrence-Free Survival (RFS) in Patients With Resected High-Risk Stage II Melanoma Compared to Placebo in the Adjuvant Setting
2021-09-17 11:15 ET
Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) in Combination With Chemotherapy for Certain Patients With Locally Recurrent Unresectable or Metastatic Triple-Negative Breast Cancer Whose Tumors Express PD-L1 (CPS ≥10)
2021-09-08 10:45 ET
Merck To Present New Data From Its Broad Oncology Portfolio and Pipeline at ESMO 2021, Including in Earlier Stages of Cancer
2021-09-07 10:45 ET
Merck to Present at the Morgan Stanley 19th Annual Healthcare Conference
2021-09-07 10:45 ET
Merck’s KEYTRUDA® (pembrolizumab) Approved in China in Combination With Chemotherapy for First-Line Treatment of Patients With Locally Advanced Unresectable or Metastatic Esophageal or Gastroesophageal Junction (GEJ) Carcinoma
2021-09-01 10:45 ET
Merck and Ridgeback Biotherapeutics Announce Initiation of Pivotal Phase 3 MOVe-AHEAD Study Evaluating Molnupiravir for Post-Exposure Prophylaxis of COVID-19 Infection
2021-08-31 20:05 ET
FDA Approves Updated Indication for Merck’s KEYTRUDA® (pembrolizumab) for Treatment of Certain Patients With Urothelial Carcinoma (Bladder Cancer)
2021-08-26 10:45 ET
Merck’s KEYTRUDA® (pembrolizumab) Receives Two New Approvals in Japan
2021-08-25 10:45 ET
Merck Announces VAXNEUVANCE™ (Pneumococcal 15-valent Conjugate Vaccine) Met Key Immunogenicity and Safety Endpoints in Phase 3 Pivotal Trial Evaluating Use in Infants, PNEU-PED (V114-029)
2021-08-20 20:45 ET
Leslie A. Brun Resigns from Merck Board of Directors
2021-08-18 12:46 ET
Merck Has Been Named One of the Top Employers in New York by Fortune
2021-08-13 23:00 ET
FDA Approves Merck’s Hypoxia-Inducible Factor-2 Alpha (HIF-2α) Inhibitor WELIREG™ (belzutifan) for the Treatment of Patients With Certain Types of Von Hippel-Lindau (VHL) Disease-Associated Tumors
2021-08-11 22:30 ET
FDA Approves KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Combination for First-Line Treatment of Adult Patients With Advanced Renal Cell Carcinoma (RCC)
2021-08-11 12:47 ET
Merck Named by Seramount As One of the Best Companies for Multicultural Women
2021-08-10 10:45 ET
FDA Accepts Application for Merck’s KEYTRUDA® (pembrolizumab) as Single Agent for Certain Patients With MSI-H/dMMR Advanced Endometrial Carcinoma
2021-08-10 10:42 ET
FDA Grants Priority Review to Merck’s Supplemental Biologics License Application for KEYTRUDA® (pembrolizumab) as Adjuvant Therapy in Certain Patients With Renal Cell Carcinoma (RCC) Following Surgery
2021-08-05 10:45 ET
Merck’s KEYTRUDA® (pembrolizumab) Significantly Prolonged Recurrence-Free Survival (RFS) Compared to Placebo as Adjuvant Therapy for Patients With Stage II Resected High-Risk Melanoma in Phase 3 KEYNOTE-716 Trial
2021-08-04 12:49 ET
Merck Has Earned the Top Spot on Forbes' 2021 List of 'Best Employers for New Graduates'
2021-07-29 16:30 ET
Merck Announces Appointment of Cristal N. Downing as Chief Communications & Public Affairs Officer
2021-07-29 10:30 ET
Merck Announces Second-Quarter 2021 Financial Results
2021-07-28 12:51 ET
Merck Recognized on Best Places to Work for Disability Inclusion List and Received Perfect Score on the Disability Equality Index (DEI)
2021-07-27 17:34 ET
Merck Announces Fourth-Quarter 2021 Dividend
2021-07-27 10:45 ET
Merck Announces Phase 3 KEYNOTE-355 Trial Met Primary Endpoint of Overall Survival (OS) in Patients with Metastatic Triple-Negative Breast Cancer Whose Tumors Expressed PD-L1 (CPS ≥10)
2021-07-27 10:30 ET
FDA Approves KEYTRUDA® (pembrolizumab) for Treatment of Patients With High-Risk Early-Stage Triple-Negative Breast Cancer in Combination With Chemotherapy as Neoadjuvant Treatment, Then Continued as Single Agent as Adjuvant Treatment After Surgery
2021-07-22 10:45 ET
FDA Approves KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Combination for Patients With Certain Types of Advanced Endometrial Carcinoma
2021-07-21 11:14 ET
VERQUVO® (vericiguat) Approved in the European Union
2021-07-20 10:00 ET
Merck Presents New Data from Ongoing Phase 2a Clinical Trial Evaluating the Safety, Tolerability and Pharmacokinetics of Investigational, Once-Monthly, Oral Islatravir for HIV-1 Prevention at IAS 2021
2021-07-16 21:15 ET
Merck Announces U.S. FDA Approval of VAXNEUVANCE™ (Pneumococcal 15-valent Conjugate Vaccine) for the Prevention of Invasive Pneumococcal Disease in Adults 18 Years and Older Caused by 15 Serotypes
2021-07-15 17:30 ET
KEYTRUDA® (pembrolizumab) Plus Chemotherapy Before Surgery and Continued as a Single Agent After Surgery Showed Statistically Significant Event-Free Survival (EFS) Result Versus Neoadjuvant Chemotherapy Alone in High-Risk Early-Stage TNBC
2021-07-12 10:55 ET
Merck Announces Presentation of New Data from Broad HIV Program at IAS 2021
2021-07-12 10:45 ET
Interim Results from Phase 2/3 Studies of Molnupiravir, an Investigational Oral Antiviral Therapeutic for Mild to Moderate COVID-19, Presented at the European Congress of Clinical Microbiology & Infectious Diseases (ECCMID)
2021-07-06 10:45 ET
FDA Approves Expanded Indication for Merck’s KEYTRUDA® (pembrolizumab) in Locally Advanced Cutaneous Squamous Cell Carcinoma (cSCC)
2021-07-01 20:05 ET
Merck Provides Update on KEYTRUDA® (pembrolizumab) Indication in Third-Line Gastric Cancer in the US
2021-06-30 20:00 ET
Merck to Hold Second-Quarter 2021 Sales and Earnings Conference Call on July 29
2021-06-29 13:05 ET
Merck Animal Health Survey Reveals Pet Owners Need Advice Navigating Their Pets' Transition to Normalcy
2021-06-29 12:30 ET
OneTen Launches Technology Platform to Create and Enable One Million Career Opportunities for Black Talent Over the Next 10 Years
2021-06-29 10:45 ET
European Commission Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy for Certain Patients With Esophageal Cancer or HER2-Negative Gastroesophageal Junction (GEJ) Adenocarcinoma
2021-06-24 15:00 ET
Merck Appoints Michael Klobuchar Chief Strategy Officer
2021-06-24 10:45 ET
LYNPARZA® (olaparib) Approved in China for the Treatment of Certain Patients with BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer
2021-06-22 10:45 ET
Merck Announces Phase 3 KEYNOTE-826 Trial Met Dual Primary Endpoints of Overall Survival (OS) and Progression-Free Survival (PFS) in Patients With Persistent, Recurrent or Metastatic Cervical Cancer
2021-06-17 14:38 ET
MSD Announces Supply Agreement with U.S. Government for Molnupiravir, an Investigational Oral Antiviral Candidate for Treatment of Mild to Moderate COVID-19
2021-06-17 10:45 ET
Merck to Participate in the Guggenheim Biopharma Strategy Series
2021-06-16 12:00 ET
Merck Announces the Kenneth C. Frazier Award for Maternal Health Equity to Accelerate Progress towards Improved Birth Outcomes for All
2021-06-09 10:45 ET
Merck Announces Supply Agreement with U.S. Government for Molnupiravir, an Investigational Oral Antiviral Candidate for Treatment of Mild to Moderate COVID-19
2021-06-07 20:30 ET
MSD Animal Health to Acquire Assets of LIC Automation Ltd.
2021-06-07 10:45 ET
New Data on KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Versus Sunitinib in First-Line Treatment for Patients With Advanced Renal Cell Carcinoma From Pivotal Phase 3 CLEAR/KEYNOTE-581 Trial Presented at 2021 ASCO Annual Meeting
2021-06-03 21:00 ET
Merck’s KEYTRUDA® (pembrolizumab) Given After Surgery Reduced the Risk of Disease Recurrence or Death by 32% Versus Placebo as Adjuvant Therapy in Patients With Renal Cell Carcinoma (RCC)
2021-06-03 21:00 ET
LYNPARZA® (olaparib) Reduced the Risk of Invasive Disease Recurrence or Death by 42% Versus Placebo in Adjuvant Treatment of Patients With Germline BRCA Mutations and High-Risk HER2-Negative Early Breast Cancer in Phase 3 OlympiA Trial
2021-06-03 10:45 ET
Merck Announces Completion of Organon & Co. Spinoff
2021-06-01 10:45 ET
Sanofi and Merck's first and only six-in-one pediatric combination vaccine now available in the United States
2021-06-01 10:45 ET
Merck and Sanofi’s First and Only Six-in-One Pediatric Combination Vaccine Now Available in the United States
2021-05-25 18:04 ET
Merck Announces Third-Quarter 2021 Dividend
2021-05-24 10:45 ET
Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) in Combination With Chemotherapy as First-Line Treatment for Certain Patients With Esophageal Cancer or HER2-Negative Gastroesophageal Junction (GEJ) Adenocarcinoma
2021-05-20 10:45 ET
Merck Announces Positive Topline Results from PNEU-DIRECTION (V114-027) and PNEU-PLAN (V114-024) Phase 3 Pediatric Studies for V114, Merck’s Investigational 15-valent Pneumococcal Conjugate Vaccine
2021-05-17 11:00 ET
Gabrielle Union-Wade Joins 'Don't Skip' Campaign to Encourage Doctor Well-Visits and Recommended Vaccinations
2021-05-13 10:45 ET
Merck Announces Phase 3 KEYNOTE-522 Trial Met Dual Primary Endpoint of Event-Free Survival (EFS) in Patients With High-Risk Early-Stage Triple-Negative Breast Cancer (TNBC)
2021-05-07 17:01 ET
Merck Declares Record Date and Dividend for the Organon & Co. Spinoff
2021-05-06 10:45 ET
Merck Highlights Scientific Data at 2021 ASCO Annual Meeting Across More Than 20 Cancer Types From Broad Oncology Research Program
2021-05-06 10:30 ET
Merck and Eisai Receive Priority Review From FDA for KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Applications for Advanced Renal Cell Carcinoma and for Advanced Endometrial Carcinoma
2021-05-05 20:05 ET
FDA Approves Merck’s KEYTRUDA® (pembrolizumab) Combined With Trastuzumab and Chemotherapy as First-line Treatment in Locally Advanced Unresectable or Metastatic HER2-Positive Gastric or Gastroesophageal Junction Adenocarcinoma
2021-05-03 10:45 ET
Merck Hosts Organon Investor Day Outlining New Company’s Vision, Focus and Business Model for Sustained Growth
2021-04-29 10:30 ET
Merck Announces First-Quarter 2021 Financial Results
2021-04-27 10:47 ET
Merck to Hold Investor Briefing Featuring Organon on May 3
2021-04-27 10:45 ET
Amid Humanitarian Crisis in India, Merck Announces Voluntary Licensing Agreements with Five Indian Generics Manufacturers to Accelerate and Expand Global Access to Molnupiravir, an Investigational Oral Therapeutic for the Treatment of COVID-19
2021-04-26 10:45 ET
Merck Accelerates Climate Goals; Announces Carbon Neutrality in Operations by 2025
2021-04-20 12:00 ET
Better Therapeutics Appoints Dr. Risa Lavizzo-Mourey to its Board of Directors
2021-04-15 10:46 ET
Merck to Discontinue Development of MK-7110 for COVID-19
2021-04-15 10:45 ET
Merck and Ridgeback Biotherapeutics Provide Update on Progress of Clinical Development Program for Molnupiravir, an Investigational Oral Therapeutic for the Treatment of Mild-to-Moderate COVID-19
2021-04-14 12:00 ET
Merck Expands Safer Childbirth Cities Initiative to 20th Community-Led Project Advancing Maternal Health Equity During Black Maternal Health Week
2021-04-09 00:31 ET
Organon Announces Pricing of Senior Notes Offering
2021-04-08 10:45 ET
Merck’s KEYTRUDA® (pembrolizumab) Demonstrated Superior Disease-Free Survival (DFS) Compared With Placebo as Adjuvant Therapy in Patients With Renal Cell Carcinoma (RCC) Following Surgery
2021-04-06 20:10 ET
Organon Announces Proposed Senior Notes Offering
2021-04-01 12:30 ET
Merck Completes Acquisition of Pandion Therapeutics
2021-03-30 11:30 ET
Merck Announces Acquisition of Alydia Health on behalf of its Planned Spinoff of Organon
2021-03-30 10:45 ET
Merck Receives Positive EU CHMP Opinion for Updated Label of KEYTRUDA® (pembrolizumab) To Include Results of Phase 3 KEYNOTE-361 Trial in Certain Adult Patients with Locally Advanced or Metastatic Urothelial Cancer
2021-03-29 20:15 ET
Merck Receives Complete Response Letter From US FDA for Supplemental Biologics License Application (sBLA) for KEYTRUDA® (pembrolizumab) in High-Risk Early-Stage Triple-Negative Breast Cancer (TNBC)
2021-03-29 10:45 ET
Merck to Hold First-Quarter 2021 Sales and Earnings Conference Call on April 29
2021-03-24 10:45 ET
Merck Appoints Caroline Litchfield Chief Financial Officer
2021-03-23 10:45 ET
FDA Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Platinum- and Fluoropyrimidine-Based Chemotherapy for Treatment of Certain Patients With Locally Advanced or Metastatic Esophageal or Gastroesophageal Junction (GEJ) Carcinoma
2021-03-19 10:45 ET
KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Significantly Improved Progression-Free Survival and Overall Survival Versus Chemotherapy in Patients With Advanced Endometrial Cancer Following Prior Platinum-Based Chemotherapy in Phase 3 Study
2021-03-17 20:27 ET
Merck Announces Filing of Form 10 Registration Statement in Connection with Planned Spinoff of Organon & Co.
2021-03-17 11:00 ET
European Commission Approves Expanded Indication for Merck’s KEYTRUDA® (pembrolizumab) in Adult and Pediatric Patients With Relapsed or Refractory Classical Hodgkin Lymphoma (cHL)
2021-03-17 10:45 ET
Mike Nally to Leave Merck; Frank Clyburn to Lead All Merck Human Health
2021-03-16 10:45 ET
Merck Receives Priority Review From FDA for New Drug Application for HIF-2α Inhibitor Belzutifan (MK-6482)
2021-03-16 07:00 ET
Merck KGaA, Darmstadt, Germany, Reports Topline Data for Bintrafusp Alfa as Second-Line Monotherapy Treatment in Biliary Tract Cancer
2021-03-15 10:47 ET
Merck to Host Investor Briefing to Discuss Broad HIV Development Program and Newly Announced Collaboration with Gilead
2021-03-15 10:45 ET
Gilead and Merck Announce Agreement to Jointly Develop and Commercialize Long-Acting, Investigational Treatment Combinations of Lenacapavir and Islatravir in HIV
2021-03-08 16:40 ET
Merck Presents Results from Phase 1 Trial Evaluating Investigational Islatravir Subdermal Implant for the Prevention of HIV-1 Infection at CROI 2021
2021-03-06 05:01 ET
Ridgeback Biotherapeutics and Merck Announce Preliminary Findings from a Phase 2a Trial of Investigational COVID-19 Therapeutic Molnupiravir
2021-03-04 11:45 ET
Merck Begins Tender Offer to Acquire Pandion Therapeutics
2021-03-03 11:45 ET
Merck to Present at the Barclays Global Healthcare Conference
2021-03-03 11:45 ET
Merck to Present New Data from Various HIV Research and Development Programs at CROI 2021
2021-03-02 21:30 ET
Merck to Help Produce Johnson & Johnson’s COVID-19 Vaccine; BARDA to Provide Merck With Funding to Expand Merck’s Manufacturing Capacity for COVID-19 Vaccines and Medicines
2021-03-02 13:00 ET
Merck Announces Fifth Round of Global Grants to Tackle Maternal Mortality and Promote Health Equity Worldwide
2021-03-01 21:05 ET
Merck Provides Update on KEYTRUDA® (pembrolizumab) Indication in Metastatic Small Cell Lung Cancer in the US
2021-03-01 11:45 ET
U.S. FDA Accepts Merck’s Gefapixant New Drug Application for Review
2021-02-25 21:30 ET
Merck Animal Health Completes Acquisition of Poultry Sense Limited
2021-02-25 11:45 ET
Merck to Acquire Pandion Therapeutics
2021-02-24 11:45 ET
Merck to Present at the Cowen 41st Annual Health Care Conference
2021-02-17 11:55 ET
Independent Data Monitoring Committee Concludes OlympiA Trial of LYNPARZA® (olaparib) Crossed Superiority Boundary for Invasive Disease-Free Survival vs. Placebo at Planned Interim Analysis
2021-02-13 18:01 ET
KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Demonstrated Superior Progression-Free Survival (PFS) and Overall Survival (OS) Versus Sunitinib as First-Line Treatment for Patients With Advanced Renal Cell Carcinoma
2021-02-04 11:45 ET
Merck Announces Fourth-Quarter and Full-Year 2020 Financial Results
2021-02-04 11:40 ET
Kenneth C. Frazier to Retire as Merck CEO; Board Elects Robert M. Davis as Successor; Frazier to Continue as Executive Chairman
2021-02-01 11:45 ET
Dr. Stephen Mayo Elected to Merck Board of Directors
2021-02-01 11:30 ET
Merck Receives Positive EU CHMP Opinion for Expanded Approval of KEYTRUDA® (pembrolizumab) in Certain Patients With Relapsed or Refractory Classical Hodgkin Lymphoma
2021-01-30 00:23 ET
Merck Presents Results From Head-to-Head Phase 3 KEYNOTE-598 Trial Evaluating KEYTRUDA® (pembrolizumab) in Combination With Ipilimumab Versus KEYTRUDA Monotherapy in Certain Patients With Metastatic Non-Small Cell Lung Cancer
2021-01-27 13:00 ET
Merck Announces Second Cohort of Safer Childbirth Cities Organizations Committed to Improving Maternal Health Equity and Reducing Preventable Maternal Deaths in the US
2021-01-26 18:15 ET
Merck Announces Second-Quarter 2021 Dividend
2021-01-26 14:06 ET
Merck Presents Interim Findings from Phase 2a Clinical Trial Evaluating Investigational Once-Monthly Oral Islatravir for the Prevention of HIV-1 Infection at HIVR4P 2021
2021-01-26 11:45 ET
European Commission Approves KEYTRUDA® (pembrolizumab) as First-Line Treatment in Adult Patients With Metastatic Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Colorectal Cancer
2021-01-25 11:45 ET
Merck Discontinues Development of SARS-CoV-2/COVID-19 Vaccine Candidates; Continues Development of Two Investigational Therapeutic Candidates
2021-01-20 11:45 ET
Merck Announces U.S. FDA Approval of VERQUVO® (vericiguat)
2021-01-12 11:45 ET
U.S. FDA Accepts for Priority Review the Biologics License Application for V114, Merck’s Investigational 15-valent Pneumococcal Conjugate Vaccine, for Use in Adults 18 Years of Age and Older
2021-01-08 11:45 ET
Merck to Hold Fourth-Quarter and Full-Year 2020 Sales and Earnings Conference Call on February 4
2021-01-04 11:45 ET
Merck to Present at the 39th Annual J.P. Morgan Healthcare Conference
2020-12-28 11:45 ET
LYNPARZA® (olaparib) Receives Three New Approvals in Japan
2020-12-23 11:45 ET
Merck Announces Supply Agreement with U.S. Government for Initial Doses of Investigational Biological Therapy for the Treatment of Patients with Severe and Critical COVID-19
2020-12-17 11:45 ET
FDA Grants Priority Review to Merck’s Supplemental Biologics License Application for KEYTRUDA® (pembrolizumab) Plus Chemotherapy as First-Line Treatment for Locally Advanced Unresectable or Metastatic Esophageal and Gastroesophageal Junction Cancer
2020-12-16 11:45 ET
KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Combination Demonstrated Statistically Significant Improvement in Overall Survival, Progression-Free Survival and Objective Response Rate Versus Chemotherapy in Patients With Advanced...
2020-12-11 12:10 ET
Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) as First-Line Treatment in Adult Patients With Metastatic Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Colorectal Cancer
2020-12-03 22:47 ET
BetterInvesting™ Magazine Chooses United Rentals As "Growth" Stock and Merck As "Undervalued" For March 2021 Issue
2020-11-30 11:45 ET
Merck to Present at the 2020 Evercore ISI 3rd Annual HealthCONx Virtual Conference
2020-11-23 14:06 ET
Merck Animal Health Survey Reveals First-Time Dog Owners Need Support
2020-11-23 11:47 ET
Merck Submits Applications for Licensure of V114, the Company’s Investigational 15-valent Pneumococcal Conjugate Vaccine, for Use in Adults to the U.S. FDA and European Medicines Agency
2020-11-23 11:45 ET
Merck to Acquire OncoImmune
2020-11-17 18:25 ET
Merck Announces First-Quarter 2021 Dividend
2020-11-16 11:45 ET
Merck Advances Phase 3 Trial to Evaluate Investigational Islatravir as Once-Monthly Oral PrEP for Women at High Risk for Acquiring HIV-1
2020-11-13 21:10 ET
FDA Approves Merck’s KEYTRUDA® (pembrolizumab) in Combination With Chemotherapy for Patients With Locally Recurrent Unresectable or Metastatic Triple‑Negative Breast Cancer Whose Tumors Express PD-L1 (CPS ≥10)
2020-11-10 11:45 ET
KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Demonstrated Statistically Significant Improvement in Progression-Free Survival (PFS), Overall Survival (OS) and Objective Response Rate (ORR) Versus Sunitinib as First-Line Treatment for Patients…
2020-11-09 21:10 ET
Merck Announces KEYNOTE-598 Trial Evaluating KEYTRUDA® (pembrolizumab) in Combination With Ipilimumab Versus KEYTRUDA Monotherapy in Certain Patients With Metastatic Non-Small Cell Lung Cancer To Stop for Futility and Patients to Discontinue...
2020-11-05 11:52 ET
Pappas Capital Portfolio Company VelosBio to be Acquired by Merck
2020-11-05 11:45 ET
LYNPARZA® (olaparib) Approved in the EU for Treatment of BRCA1/2-Mutated Metastatic Castration-Resistant Prostate Cancer (mCRPC)
2020-11-05 11:45 ET
LYNPARZA® (olaparib) in Combination with Bevacizumab Approved in the EU as First-Line Maintenance Treatment for HRD-Positive Advanced Ovarian Cancer
2020-11-05 11:30 ET
Merck to Acquire VelosBio
2020-10-27 10:45 ET
Merck Announces Third-Quarter 2020 Financial Results
2020-10-22 12:00 ET
Merck Donates $500,000 to Support River Blindness and Lymphatic Filariasis Elimination Efforts
2020-10-21 10:45 ET
Merck to Present New Data from its Extensive Infectious Diseases and Vaccines Pipeline and Portfolio During IDWeek 2020
2020-10-20 10:45 ET
Merck Announces Positive Topline Results from Two Additional Phase 3 Adult Studies Evaluating V114, Merck’s Investigational 15-valent Pneumococcal Conjugate Vaccine
2020-10-16 18:00 ET
Merck Presents Three-Year Survival Data for KEYTRUDA® (pembrolizumab) in Combination With Chemotherapy and Updated Phase 1/2 Data for Investigational Quavonlimab (MK-1308) in Combination With KEYTRUDA in Advanced Non‑Small Cell Lung Cancer
2020-10-15 10:45 ET
FDA Approves Expanded Indication for Merck’s KEYTRUDA® (pembrolizumab) in Adult Patients With Relapsed or Refractory Classical Hodgkin Lymphoma (cHL)
2020-10-14 12:00 ET
Merck Issues 2019/2020 Corporate Responsibility Report
2020-10-08 10:45 ET
Merck Announces Week 96 Data from Phase 2b Study Evaluating Islatravir in Combination With Doravirine in Adults With HIV-1 Infection
2020-10-02 12:00 ET
Merck Announces Retirement of Dr. Roger M. Perlmutter; Dr. Dean Y. Li Appointed as President, Merck Research Laboratories
2020-10-01 10:45 ET
Merck to Present New Data from the Company’s Diverse HIV Portfolio and Pipeline at HIV Glasgow 2020
2020-10-01 10:30 ET
Merck to Hold Third-Quarter 2020 Sales and Earnings Conference Call on October 27
2020-09-28 10:45 ET
Merck Animal Health Supports Rabies Elimination by 2030 on World Rabies Day
2020-09-21 16:30 ET
Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy Reduced Risk of Death by 27% Versus Chemotherapy as First-Line Treatment for Locally Advanced or Metastatic Esophageal Cancer
2020-09-21 12:25 ET
First-Line Treatment With Merck’s KEYTRUDA® (pembrolizumab) Doubled Five-Year Survival Rate (31.9%) Versus Chemotherapy (16.3%) in Certain Patients With Metastatic Non-Small Cell Lung Cancer Whose Tumors Express PD-L1 (TPS >50%)
2020-09-21 10:45 ET
LYNPARZA® (olaparib) Receives Positive Opinion from EU CHMP for Treatment of BRCA1/2 Metastatic Castration-Resistant Prostate Cancer (mCRPC)
2020-09-21 10:45 ET
LYNPARZA® (olaparib) Recommended for Approval in EU by CHMP as First-Line Maintenance Treatment with Bevacizumab for HRD-Positive Advanced Ovarian Cancer
2020-09-20 16:30 ET
LYNPARZA Reduced Risk of Death by 31% vs. Enzalutamide or Abiraterone for Men with BRCA1/2 or ATM-Mutated Metastatic Castration Resistant Prostate Cancer Who Progressed Following Enzalutamide or Abiraterone in Phase 3 PROfound Trial
2020-09-20 16:30 ET
LYNPARZA® (olaparib) Reduced the Risk of Death by 31% in BRCA1/2 or ATM-mutated Metastatic Castration-Resistant Prostate Cancer in Phase III Profound Trial
2020-09-20 14:20 ET
Merck Presents Promising New Data for Three Investigational Medicines From Diverse and Expansive Oncology Pipeline at ESMO Virtual Congress 2020
2020-09-20 12:25 ET
Merck and Eisai Present First-Time Data From Two Studies Evaluating KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) in Seven Different Tumor Types at ESMO Virtual Congress 2020
2020-09-19 14:20 ET
Merck’s KEYTRUDA® (pembrolizumab) Reduced the Risk of Distant Metastasis or Death by 40% Versus Placebo as Adjuvant Treatment in Resected, High-Risk Stage III Melanoma
2020-09-18 10:45 ET
LYNPARZA® (olaparib) Improved Median Progression-Free Survival to Over Four and a Half Years Compared to 13.8 Months with Placebo for Patients with BRCA-Mutated Advanced Ovarian Cancer
2020-09-16 10:45 ET
Merck to Hold Investor Briefing Following ESMO Virtual Congress 2020
2020-09-15 10:45 ET
Merck to Present at the 2020 Cantor Fitzgerald Virtual Global Healthcare Conference
2020-09-10 10:45 ET
Merck to Present at the Morgan Stanley 18th Annual Virtual Global Healthcare Conference
2020-09-09 10:45 ET
Merck Announces Positive Topline Results from Two Phase 3 Adult Studies Evaluating V114, Merck’s Investigational 15-valent Pneumococcal Conjugate Vaccine, Including Pivotal Trial
2020-09-08 10:45 ET
Merck’s Gefapixant (45 mg Twice Daily) Significantly Decreased Cough Frequency Compared to Placebo at Week 12 and 24 in Patients with Refractory or Unexplained Chronic Cough
2020-09-04 10:45 ET
Merck to Present at the Citi 15th Annual BioPharma Virtual Conference
2020-09-02 10:45 ET
New Scientific Data at the ESMO Virtual Congress 2020 Reflect Merck’s Commitment to Advancing Cancer Research and Care
2020-09-01 13:00 ET
TriRx Pharmaceutical Services acquires MSD Animal Health manufacturing site located in Segré-en Anjou Bleu, France including long-term supply agreement
2020-08-24 10:45 ET
Merck’s KEYTRUDA® (pembrolizumab) Receives Two New Approvals in Japan
2020-08-19 10:45 ET
Merck’s KEYTRUDA® (pembrolizumab) in Combination With Chemotherapy Significantly Improved Overall Survival and Progression-Free Survival Compared With Chemotherapy in Locally Advanced or First-Line Metastatic Esophageal Cancer
2020-08-19 06:00 ET
Ivermectin Triple Therapy Protocol for COVID-19 Released to Australian GPs for Infected Elderly and Frontline Workers
2020-08-13 06:30 ET
QBiotics Announces Clinical Collaboration with MSD Targeting Unresectable Melanoma
2020-08-05 11:00 ET
Merck Animal Health Completes Acquisition of IdentiGEN
2020-08-04 09:00 ET
Merck and Hanmi Pharmaceutical Enter into Licensing Agreement to Develop Efinopegdutide, an Investigational Once-Weekly Therapy for Nonalcoholic Steatohepatitis (NASH)
2020-08-03 10:30 ET
Merck Animal Health Completes Acquisition of Worldwide Rights to VECOXAN® Brand of Parasiticides for Ruminant Portfolio
2020-07-31 10:45 ET
 Merck Announces Second-Quarter 2020 Financial Results
2020-07-30 10:45 ET
Merck Announces Two US Regulatory Milestones for KEYTRUDA® (pembrolizumab) in Triple-Negative Breast Cancer (TNBC)
2020-07-29 10:45 ET
FDA Grants Breakthrough Therapy Designation to Merck’s Novel HIF-2α Inhibitor MK-6482 for Treatment of Certain Patients With Von Hippel-Lindau Disease- Associated Renal Cell Carcinoma
2020-07-28 17:30 ET
Merck Announces Fourth-Quarter 2020 Dividend
2020-07-16 11:01 ET
Oncorus Announces Clinical Trial Collaboration with Merck to Evaluate the Combination of Oncorus’ ONCR-177 with Merck’s KEYTRUDA® (pembrolizumab)...
2020-07-16 10:45 ET
FDA Grants Priority Review to Merck’s New Drug Application for Vericiguat
2020-07-09 20:30 ET
Merck Animal Health Receives U.S. FDA Approval of BRAVECTO® (fluralaner) Monthly Chews
2020-07-09 10:45 ET
FDA Grants Priority Review to Merck’s Supplemental Biologics License Application for KEYTRUDA® (pembrolizumab) for Second-Line Treatment of Patients With Relapsed or Refractory Classical Hodgkin Lymphoma
2020-07-08 20:30 ET
Merck Announces Appointment of Organon & Co. General Counsel
2020-07-08 10:55 ET
LYNPARZA® (olaparib) Approved in the EU for Germline BRCA-mutated Metastatic Pancreatic Cancer
2020-07-08 10:45 ET
Merck and Eisai Receive Complete Response Letter for KEYTRUDA® (pembrolizumab) plus LENVIMA® (lenvatinib) Combination as First-Line Treatment for Unresectable Hepatocellular Carcinoma
2020-07-06 10:45 ET
Merck Announces New Analyses Showing Additional Safety and Efficacy Data for Investigational Islatravir in Combination with Doravirine in Adults with HIV-1 Infection
2020-07-02 06:00 ET
Merck Animal Health Completes Acquisition of U.S. Rights to SENTINEL® Brand of Combination Parasiticides for Companion Animals
2020-07-01 20:30 ET
Merck and Ridgeback Bio Announce Closing of Collaboration and Licensing Transaction
2020-07-01 10:45 ET
Merck to Hold Second-Quarter 2020 Sales and Earnings Conference Call on July 31
2020-06-29 20:20 ET
FDA Approves Merck’s KEYTRUDA® (pembrolizumab) for First-Line Treatment of Patients With Unresectable or Metastatic MSI-H or dMMR Colorectal Cancer
2020-06-24 21:29 ET
FDA Approves Merck’s KEYTRUDA® (pembrolizumab) for the Treatment of Patients with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (cSCC) that is Not Curable by Surgery or Radiation
2020-06-24 10:45 ET
Merck Underscores Commitment to HIV with New Data Analyses to be Presented at AIDS 2020: Virtual
2020-06-22 10:45 ET
Merck Announces That V114, Its Investigational 15-valent Pneumococcal Conjugate Vaccine, Met Safety and Immunogenicity Objectives in Initial Phase 3 Studies in Adults
2020-06-22 10:30 ET
Merck’s KEYTRUDA® (pembrolizumab) Approved in China for Second-Line Treatment of Patients with Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma Whose Tumors Express PD-L1 (CPS ≥10)
2020-06-19 12:29 ET
Merck Completes Acquisition of Themis
2020-06-17 20:30 ET
Merck Animal Health Completes Acquisition of Quantified Ag®
2020-06-17 10:45 ET
FDA Approves Second Biomarker-Based Indication for Merck’s KEYTRUDA® (pembrolizumab), Regardless of Tumor Type
2020-06-17 10:30 ET
Merck Prices $4.5 Billion Debt Offering
2020-06-16 17:15 ET
Merck and Pfizer’s SGLT2 Inhibitor STEGLATROTM (ertugliflozin) Meets Primary Endpoint in VERTIS CV Trial for Patients with Type 2 Diabetes and Atherosclerotic Cardiovascular Disease
2020-06-15 12:00 ET
Merck Announces Call for Proposals for Second Cohort of Safer Childbirth Cities, Expanding Maternal Health Support Across US Cities
2020-06-12 22:40 ET
FDA Approves Merck’s GARDASIL 9 for the Prevention of Certain HPV-Related Head and Neck Cancers
2020-06-09 20:05 ET
Merck Provides Update on Phase 3 KEYNOTE-361 Trial Evaluating KEYTRUDA® (pembrolizumab) as Monotherapy and in Combination with Chemotherapy in Patients with Advanced or Metastatic Urothelial Carcinoma
2020-06-05 10:50 ET
FDA Approves Merck’s RECARBRIO™ (imipenem, cilastatin, and relebactam) for the Treatment of Adults with Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia (HABP/VABP)
2020-06-01 10:45 ET
LYNPARZA® (olaparib) Receives Positive Opinion from EU CHMP for First-Line Maintenance Treatment of Patients with Germline BRCA-Mutated Metastatic Pancreatic Cancer
2020-05-28 22:37 ET
KEYTRUDA® (pembrolizumab) plus LENVIMA® (lenvatinib) Combination Demonstrated Clinically Meaningful Tumor Response Rates in Unresectable Hepatocellular Carcinoma and Advanced Renal Cell Carcinoma
2020-05-28 21:00 ET
Merck’s KEYTRUDA® (pembrolizumab) Superior to Standard of Care Chemotherapy in Patients with MSI-H Colorectal Cancer
2020-05-26 16:37 ET
Merck Announces Third-Quarter 2020 Dividend
2020-05-26 10:51 ET
Merck and Ridgeback Bio Collaborate to Advance Development of Novel Antiviral Candidate, EIDD-2801
2020-05-26 10:49 ET
IAVI and Merck Collaborate to Develop Vaccine Against SARS-CoV-2
2020-05-26 10:47 ET
Merck to Acquire Themis
2020-05-26 10:45 ET
Merck to Announce Multiple Scientific Efforts to Combat COVID-19
2020-05-20 10:55 ET
LYNPARZA® (olaparib) Approved by FDA for Treatment of HRR Gene-Mutated Metastatic Castration-Resistant Prostate Cancer That Has Progressed Following Prior Treatment with Enzalutamide or Abiraterone
2020-05-19 11:00 ET
 Infectious Disease Connect and ILÚM Health Solutions Combine to Advance Precision Treatment of Infectious Diseases and Antimicrobial Stewardship
2020-05-18 20:30 ET
CORRECTING and REPLACING Merck Announces Appointment of Organon & Co. Chief Financial Officer and Chief Information Officer
2020-05-14 10:45 ET
Merck to Present at the UBS Virtual Global Healthcare Conference
2020-05-13 21:00 ET
New Combination Data for Merck’s KEYTRUDA® (pembrolizumab) Demonstrated Clinical Benefit in Stage III Non-Small Cell Lung Cancer (NSCLC) and Reinforce Long-Term Survival in Metastatic NSCLC
2020-05-06 10:45 ET
Results of Phase 3 Trial Evaluating the Efficacy and Safety of Merck’s RECARBRIO™ (Imipenem, Cilastatin, and Relebactam) Versus Piperacillin and Tazobactam in Adult Patients with HABP/VABP Now Available
2020-05-05 10:45 ET
Merck Commits Additional $10 Million to COVID-19 Relief Efforts to Help Disparately Impacted Patients and Communities
2020-04-01 20:00 ET
Medical Professionals Across Merck & Co., Inc., Pfizer Inc., and Eli Lilly and Company Activate to Support Health Systems, First Responders and Patients Amid COVID-19 Pandemic
2020-03-25 21:00 ET
Merck to Donate 300,000 Masks to New Jersey for COVID-19 Emergency Response
2020-03-20 21:01 ET
Merck Recommends Rejection of TRC Capital’s “Mini-Tender” Offer
2020-02-27 11:45 ET
Merck to Present at the Cowen Health Care Conference
2020-02-12 11:45 ET
Merck’s KEYTRUDA® (pembrolizumab) in Combination with Chemotherapy Met Primary Endpoint of Progression-Free Survival (PFS) as First-Line Treatment for Metastatic Triple-Negative Breast Cancer (mTNBC)
2020-01-28 07:00 ET
Lung Cancer Study Shows Barriers in Patient Access to Care in Europe
2020-01-06 16:07 ET
Moore Kuehn, PLLC Encourages Investors of KEM, ARQL, THOR, and LOGM to Contact the Firm
2019-12-12 20:49 ET
SHAREHOLDER ALERT: WeissLaw LLP Investigates ArQule, Inc.
2019-11-25 11:45 ET
New Survey of Young Adults Uncovers Low Levels of Accurate Knowledge About HIV Transmission Coupled with High-Risk Sexual Behaviors
2019-04-13 11:00 ET
Results of Phase 3 Trial Evaluating Merck’s ZERBAXA® (ceftolozane and tazobactam) versus Meropenem for Treatment of Adult Patients with Ventilated Nosocomial Pneumonia (VNP) to be Presented at ECCMID 2019
2019-04-11 21:45 ET
FDA Approves Expanded Monotherapy Label for Merck’s KEYTRUDA® (pembrolizumab)
2019-04-10 10:45 ET
LYNPARZA® (olaparib) Approved in EU for the Treatment of Germline BRCA-Mutated HER2-Negative Advanced Breast Cancer
2019-04-02 10:45 ET
Merck Completes Tender Offer to Acquire Immune Design
2019-04-02 10:30 ET
Merck to Hold First-Quarter 2019 Sales and Earnings Conference Call on April 30
2019-04-01 20:45 ET
Merck Completes Acquisition of Antelliq Corporation to Become Leader in Emerging Digital Technology for Livestock and Companion Animals
2019-03-14 10:45 ET
European Commission Approves Merck’s KEYTRUDA® (pembrolizumab) in Combination with Chemotherapy for First-Line Treatment of Adults with Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC)
2019-03-05 23:37 ET
Merck Prices $5.0 Billion Debt Offering
2019-03-05 11:45 ET
Merck Begins Tender Offer to Acquire Immune Design
2019-02-21 11:45 ET
Merck to Acquire Immune Design

SEC forms

Show financial reports only

SEC form 8
2025-02-04 06:45 ET
Merck reported for 2024 q4
SEC form 8
2025-02-04 06:45 ET
Merck reported for 2024 q4
SEC form 8
2025-02-04 06:45 ET
Merck published news for 2024 q4
SEC form 10
2024-11-06 16:05 ET
Merck reported for 2024 q3
SEC form 8
2024-10-31 06:44 ET
Merck published news for 2024 q3
SEC form 8
2024-10-31 06:44 ET
Merck published news for 2024 q3
SEC form 8
2024-10-31 06:44 ET
Merck published news for 2024 q3
SEC form 10
2024-08-05 00:00 ET
Merck reported for 2024 q2
SEC form 8
2024-07-30 06:41 ET
Merck published news for 2024 q2
SEC form 8
2024-07-30 06:41 ET
Merck published news for 2024 q2
SEC form 8
2024-07-30 06:41 ET
Merck published news for 2024 q2
SEC form 10
2024-05-03 00:00 ET
Merck reported for 2024 q1
SEC form 8
2024-04-25 06:41 ET
Merck published news for 2024 q1
SEC form 8
2024-04-25 06:41 ET
Merck published news for 2024 q1
SEC form 8
2024-04-25 06:41 ET
Merck reported for 2024 q1
SEC form 10
2024-02-26 16:06 ET
Merck published news for 2023 q4
SEC form 10
2024-02-26 00:00 ET
Merck published news for 2023 q4
SEC form 8
2024-02-01 00:00 ET
Merck reported for 2023 q4
SEC form 8
2024-02-01 00:00 ET
Merck published news for 2023 q4
SEC form 8
2024-02-01 00:00 ET
Merck published news for 2023 q4
SEC form 10
2023-11-03 00:00 ET
Merck reported for 2023 q3
SEC form 8
2023-10-26 06:38 ET
Merck published news for 2023 q3
SEC form 10
2023-08-07 00:00 ET
Merck reported for 2023 q2
SEC form 6
2023-08-01 06:46 ET
Merck published news for 2023 q2
SEC form 8
2023-08-01 00:00 ET
Merck published news for 2023 q2
SEC form 6
2023-06-27 14:11 ET
Merck published news for 2023 q1
SEC form 6
2023-06-27 14:10 ET
Merck published news for 2023 q1
SEC form 6
2023-06-27 14:09 ET
Merck published news for 2023 q1
SEC form 10
2023-05-05 00:00 ET
Merck reported for 2023 q1
SEC form 8
2023-04-27 00:00 ET
Merck reported for 2023 q1
SEC form 10
2023-02-24 16:22 ET
Merck reported for 2022 q4
SEC form 10
2023-02-24 00:00 ET
Merck reported for 2022 q4
SEC form 6
2023-02-02 06:42 ET
Merck published news for 2022 q4
SEC form 8
2023-02-02 00:00 ET
Merck reported for 2022 q4
SEC form 10
2022-11-03 16:28 ET
Merck reported for 2022 q3
SEC form 10
2022-11-03 00:00 ET
Merck reported for 2022 q3
SEC form 6
2022-10-27 06:38 ET
Merck published news for 2022 q3
SEC form 8
2022-10-27 00:00 ET
Merck published news for 2022 q3
SEC form 10
2022-08-05 00:00 ET
Merck reported for 2022 q2
SEC form 10
2022-08-04 17:35 ET
Merck reported for 2022 q2
SEC form 6
2022-07-28 06:36 ET
Merck published news for 2022 q2
SEC form 8
2022-07-28 00:00 ET
Merck published news for 2022 q2
SEC form 6
2022-06-15 14:22 ET
Merck published news for 2022 q1
SEC form 6
2022-06-15 14:19 ET
Merck published news for 2022 q1
SEC form 6
2022-06-15 14:07 ET
Merck published news for 2022 q1
SEC form 6
2022-05-26 16:06 ET
Merck published news for 2022 q1
SEC form 10
2022-05-05 16:28 ET
Merck reported for 2022 q1
SEC form 10
2022-05-05 00:00 ET
Merck reported for 2022 q1
SEC form 6
2022-04-28 06:35 ET
Merck published news for 2022 q1
SEC form 8
2022-04-28 00:00 ET
Merck reported for 2022 q1
SEC form 8
2022-04-21 00:00 ET
Merck published news for 2022 q1
SEC form 6
2022-04-20 18:45 ET
Merck published news for 2022 q1
SEC form 6
2022-04-04 16:34 ET
Merck published news for 2022 q1
SEC form 6
2022-03-25 16:14 ET
Merck published news for 2021 q4
SEC form 10
2022-02-25 16:44 ET
Merck published news for 2021 q4
SEC form 10
2022-02-25 00:00 ET
Merck published news for 2021 q4
SEC form 6
2022-02-03 06:39 ET
Merck published news for 2021 q4
SEC form 8
2022-02-03 00:00 ET
Merck published news for 2021 q4
SEC form 6
2021-12-10 17:25 ET
Merck published news for 2021 q3
SEC form 10
2021-11-05 16:09 ET
Merck published news for 2021 q3
SEC form 10
2021-11-05 00:00 ET
Merck published news for 2021 q3
SEC form 6
2021-10-28 06:40 ET
Merck published news for 2021 q3
SEC form 8
2021-10-28 00:00 ET
Merck published news for 2021 q3
SEC form 6
2021-08-20 16:55 ET
Merck published news for 2021 q2
SEC form 10
2021-08-09 07:07 ET
Merck published news for 2021 q2
SEC form 10
2021-08-09 00:00 ET
Merck published news for 2021 q2
SEC form 6
2021-07-29 07:01 ET
Merck published news for 2021 q2
SEC form 8
2021-07-29 00:00 ET
Merck published news for 2021 q2
SEC form 6
2021-06-21 16:34 ET
Merck published news for 2021 q1
SEC form 6
2021-06-16 14:11 ET
Merck published news for 2021 q1
SEC form 6
2021-06-16 14:07 ET
Merck published news for 2021 q1
SEC form 6
2021-06-16 14:04 ET
Merck published news for 2021 q1
SEC form 6
2021-06-03 08:06 ET
Merck published news for 2021 q1
SEC form 6
2021-05-27 10:13 ET
Merck published news for 2021 q1
SEC form 6
2021-05-05 16:31 ET
Merck published news for 2021 q1
SEC form 10
2021-05-05 16:26 ET
Merck published news for 2021 q1
SEC form 10
2021-05-05 00:00 ET
Merck published news for 2021 q1
SEC form 6
2021-04-29 06:38 ET
Merck published news for 2021 q1
SEC form 8
2021-04-29 00:00 ET
Merck published news for 2021 q1
SEC form 6
2021-04-05 16:05 ET
Merck published news for 2021 q1
SEC form 6
2021-03-26 16:19 ET
Merck published news for 2020 q4
SEC form 6
2021-03-24 16:58 ET
Merck published news for 2020 q4
SEC form 10
2021-02-25 16:34 ET
Merck published news for 2020 q4
SEC form 6
2021-02-04 11:16 ET
Merck published news for 2020 q4
SEC form 6
2021-02-04 06:50 ET
Merck published news for 2020 q4
SEC form 6
2021-02-01 07:04 ET
Merck published news for 2020 q4
SEC form 10
2020-11-05 16:55 ET
Merck published news for 2020 q3
SEC form 6
2020-10-27 06:50 ET
Merck published news for 2020 q3